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ABSTRACT 
Chung-Ping Liao 
POLYAMINES AND ALVEOLAR MACROPHAGE APOPTOSIS 
DURING PNEUMOCYSTIS PNEUMONIA 
 
Pneumocystis pneumonia (PCP) is the leading opportunistic disease in 
immunocompromised individuals, particularly in AIDS patients. The alveolar 
macrophage (AM) is the major type of cell responsible for the clearance of Pneumocystis 
organisms; however, they undergo a high rate of apoptosis during PCP due to increased 
intracellular polyamine levels. This study examined the mechanism of this polyamine 
mediated apoptosis and investigated an alternative therapy for PCP by targeting this 
mechanism. The elevated polyamine levels were determined to be caused by increased 
polyamine synthesis and uptake. Increased polyamine uptake was found to be 
AM-specific, and recruited inflammatory cells including monocytes, B cells, and CD8+ T 
cells were found to be a potential source of polyamines. The expression of the antizyme 
inhibitor (AZI), which regulates both polyamine synthesis and uptake, was found to be 
greatly up-regulated in AMs during PCP. AZI overexpression was confirmed to be the 
cause of increased polyamine synthesis and uptake and apoptosis of AMs during PCP by 
gene knockdown assays. Pneumocystis organisms and zymosan were found to induce 
AZI overexpression in AMs, suggesting that the β-glucan of the Pneumocystis cell wall is 
responsible for this AZI up-regulation. In addition, levels of mRNA, protein, and activity 
of polyamine oxidase (PAO) were also found to be increased in AMs during PCP, and its 
substrates N1-acetylspermidine and N1-acetylspermine were found to induce its 
up-regulation. These results indicate that the H2O2 generated during PAO-mediated 
 v
polyamine catabolism caused AMs to undergo apoptosis. Since increased polyamine 
uptake was demonstrated to be a pathogenic mechanism of PCP in this study, the 
potential therapeutic activity of five putative polyamine transport inhibitors against PCP 
was tested. Results showed that compound 44-Ant-44 significantly decreased pulmonary 
inflammation, organism burden, and macrophage apoptosis, and prolonged the survival 
of rats with PCP. In summary, this study demonstrated that Pneumocystis organisms 
induce AZI overexpression, leading to increased polyamine synthesis, uptake, and 
apoptosis rate in AMs and that targeting polyamine transport is a viable therapeutic 
approach against PCP. 
 
Chao-Hung Lee, Ph.D., Chair 
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INTRODUCTION 
 
Chapter 1: Pneumocystis Organisms and Pneumocystis Pneumonia 
 
Discovery 
 
Pneumocystis pneumonia (PCP) is caused by infection of the organism 
Pneumocystis. Pneumocystis was first discovered by Carlos Chagas in 1909 in a 
Trypanosome infection guinea pig model (30). Chagas mis-identified it as a novel 
morphologic form of Trypanosoma cruzi. In 1910, Antonio Carinii found Pneumocystis 
in rat lungs and also considered it a new type of trypanosome (27). In 1912, Delanoe and 
Delanoe at the Pasteur Institute recognized that the organism identified by both Chagas 
and Carinii was a new species (43) and named the organism Pneumocystis carinii to 
highlight its lung tropism, cyst-like morphology and to give credit to Carinii. 
 
Taxonomy 
 
Since the time of discovery until the late 1980s, Pneumocystis was widely thought to 
be a protozoan on the basis of its morphological features and susceptibility to 
antimicrobial drugs. Histological examination reveals that Pneumocystis exhibits trophic 
and cyst forms which are almost exclusively present in protozoa, such as Entamoeba and 
Giardia. In addition, Pneumocystis is susceptible to anti-protozoan drugs, such as 
pentamidine, trimethoprim, and sulfamethoxazole, but resistant to anti-fungal agents 
including imidazole and amphotericin B. In 1988, DNA sequencing analysis of the 
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Pneumocystis small subunit ribosomal RNA gene (16S-like rRNA) demonstrated that 
Pneumocystis carinii and Saccharomyces cerevisiae are more closely related to than 
Pneumocystis carinii and Trypanosoma brucei (49). Therefore, Pneumocystis was 
reclassified as an ascomycetous fungus. Pneumocystis species are now taxonomically 
placed in the phylum Ascomycota, class Pneumocystidomycetes, order Pneumocystidales, 
and family Pneumocystidaceae. 
 
Nomenclature 
 
Pneumocystis carinii was the only species in the genus Pneumocystis. In 1993, 
Pneumocystis isolates from different hosts were proven to exhibit stringent host 
specificity. For example, Pneumocystis organisms from humans do not infects rats and 
vice versa (62). To recognize this host specificity, a trinominal naming system was then 
implemented. For example, Pneumocystis infecting human and mice were named 
Pneumocystis carinii f.sp. hominis and Pneumocystis carinii f.sp. murina, respectively. 
This naming system has proven to be very cumbersome to use; therefore, the 
Pneumocystis naming system was further changed. Human Pneumocystis is now called 
Pneumocystis jirovecii (197) in honor of the Czech parasitologist Otto Jirovec who first 
described Pneumocystis in humans (195). Mouse Pneumocystis was renamed as 
Pneumocystis murina. Pneumocystis carinii now refers to the rat-derived Pneumocystis 
organisms. 
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Life cycle 
 
Pneumocystis has two major morphological forms in its life cycle: trophic and cyst 
forms. During Pneumocystis infection in the lung, the trophic forms predominate over the 
cyst forms by 10 fold. DNA analysis reveals that most trophic forms are haploid (241). 
The sizes of Pneumocystis trophic and mature cyst forms range from 1 to 4 μm and 8 to 
10 μm in diameter, respectively. Pneumocystis can be reproduced through both sexual 
and asexual cycles. Sexual reproduction begins from the conjugation of two trophic 
organisms to form a precyst. There are three precyst stages, including early, intermediate, 
and late stages with 2, 4, and 8 intracystic nuclei, respectively. Mature Pneumocystis 
cysts may rupture to release the trophs which can undergo vegetative growth or conjugate 
to reform a new cyst. In addition to sexual reproduction, Pneumocystis also undergoes 
asexual reproduction by binary fission like most prokaryotic cells, although Pneumocystis 
is a eukaryotic organism. The events of Pneumocystis life cycles described above are 
solely established from microscopic observations of organisms from infected animals, 
since Pneumocystis organisms cannot be cultured continuously. 
 
Cell Wall 
 
Pneumocystis cell wall is composed of complex carbohydrates and proteins. The 
main component is β-1,3-glucan. It is a linear glucose polymer with 1,3-linked 
carbohydrate core and side chains of 1,6- and 1,4-linked glucose residues (47). The main 
function of Pneumocystis β-glucan is to provide rigid structural stability for the 
organisms. Since β-glucan is not present in mammalian cells, Pneumocystis β-glucan is a 
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pathogen associated molecular pattern (PAMP) for host cells, particulary inflammatory 
cells (222). Chitin is another structural carbohydrate on the Pneumocystis cell wall, but 
its levels are much lower than those of β-glucan. 
In addition to carbohydrate meshes, Pneumocystis cell wall also contains abundant 
surface proteins. These proteins are highly glycosylated with hundreds of mannose 
residues. The major surface glycoprotein (MSG) (also known as glycoprotein A) is the 
most abundant mannoprotein on Pneumocystis. MSG has been shown to be a target of the 
mannose receptor of AMs (158). 
Pneumocystis MSG genes are located on all Pneumocystis chromosomes, 
determined by pulsed field gel electrophoresis hybridization (198). All MSG genes were 
found to reside at the ends of chromosomes (199), and they are organized as a cluster of 2 
- 4 genes in each chromosomal ends. Therefore, there are a total of approximately 100 
MSG genes in the Pneumocystis genome. Since they are located at the ends of 
chromosomes, the MSG genes are associated with telomeric sequences (216) and are 
sensitive to exonuclease digestion (199). 
Although there are about 100 MSG genes in the Pneumocystis genome, only a single 
form of MSG is expressed at a time (198). This serves as a pathogenic mechanism 
allowing Pneumocystis to evade host immune defenses. The single MSG gene expression 
is controlled by a 429 bp conserved DNA sequence located upstream of an expressing 
MSG gene termed upstream conserved sequence (UCS) (226) and a common 23 bp 
sequence called the conserved recombination junction element (CRJE) (226). An active 
MSG gene requires an UCS to be present at its 5’ end in order to be transcribed. Since 
there is only one UCS in the Pneumocystis genome, only one MSG gene can be 
expressed at one time and most MSG genes remain silent. The change in MSG expression 
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is mediated by a reciprocal recombination. A silent MSG gene must be translocated 
downstream of UCS through a homologous recombination at the CRJE site present in all 
MSG genes to become active. This recombination only happens one way in that a MSG 
gene translocates to the UCS locus, but not vise versa. 
 
Culture 
 
Animals with Pneumocystis infection have long been the only reliable source to 
obtain a large number of Pneumocystis organisms for study. Continuous depletion of 
CD4+ cells by steroid or anti-CD4 antibody is a necessary requirement to render the 
animals susceptible to Pneumocystis infection. Pneumocystis organisms are often 
introduced by transtracheal instillation one week after initiation of immunosuppression, 
and PCP usually develops after four weeks of infection. Untreated animals usually die 
within 6 - 10 weeks due to servere respiratory failure. The organism burden is increased 
over time and reaches the maxium levels right before the host’s death. 
Although long-term culture is not possible, short-term cultures with feeder cells 
have been achieved using African green monkey kidney epithelial cells (170), human 
embryonic lung fibroblasts (108), and rat alveolar epithelial cells (2). In general, these 
cell-based Pneumocystis culture systems increase the number of organisms approximately 
6 - 10 fold within the first 3 - 4 days. The organism number stays constant for 7 - 14 days 
and then decreases rapidly. The speed of Pneumocystis growth is decreased over passage, 
and the growth is stopped after 2 - 3 passages (7). 
In 1999, Merali et al. reported an axenic Pneumocystis culture system (136). This 
method grows Pneumocystis organisms in Minimal Essential Medium (MEM) with 
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Earle’s salts supplemented with horse serum, S-adenosylmethionine sulfate, 
aminobenzoic acid, putrescine, ferric pyrophosphate, cysteine, glutamine, 
N-acetyl-D-glucosamine, penicillin, and streptomycin. Pneumocystis organisms are 
cultured at 31°C in normal atmosphere on 0.4 μM pore size, collagen-coated Transwell 
inserts. Medium is changed twice daily. The doubling time of Pneumocystis organisms in 
this culture system ranges from 35 to 65 hours. The culture can be maintained up to 96 
days with a total of 12 subcultures. The cultured organisms can be frozen for reculture. 
Unfortunately, this method has remained an isolated success as no other laboratory has 
been able to reproduce it (25). 
S-adenosylmethionine (SAM), a key molecule in methylations and polyamine 
biosynthesis, is a controversial molecule in this Pneumocystis culture system. Merali et al. 
described that SAM is a critical supplement in Pneumocystis culture since Pneumocystis 
lacks the SAM synthetase (SAMS) activity and must rely on exogenous SAM supply 
(137). However, a contradictory study demonstrated the presence of a functional 
Pneumocystis SAMS gene by cloning the gene and expressing the recombinant protein 
(100). The role of SAM in supporting Pneumocystis growth is also controversial, as an 
independent group found that addition of SAM to Pneumocystis culture dramatically 
decreased the viability rather than increased the growth of Pneumocystis organisms (42). 
 
Strains 
 
There are multiple strains in each Pneumocystis species. Owing to the lack of a 
reliable in vitro culture system, typing of different Pneumocystis strains is practically 
impossible to perform by conventional microbial typing methods such as biochemical 
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reactions or serotypings since these methods require large numbers of organisms. Current 
Pneumocystis typing is achieved by determining the number and size of chromosomes or 
certain nucleotide variations. Each rat Pneumocystis strain has 13 - 15 linear 
chromosomes ranging from 300 to 700 kb (196). The nucleotide sequences of human 
Pneumocystis strains differ in the internal transcribed spacer (ITS) regions of nuclear 
rRNA (121) or mitochondrial large subunit rRNA (227) genes. At least 60 different types 
of P. jirovecii have been identified (109). 
 
Clinical Features 
 
Pneumocystis infection only occurs in immunocompromised individuals, 
particularly when the number of CD4+ T cells is lower than 200 per millimeter of blood 
(168). Patients with AIDS have the highest risk of developing PCP since CD4+ T cells 
are the target cells for HIV, and the number of CD4+ T cells is further decreased as HIV 
infection progresses. Patients with cancers, transplants, rheumatoid arthritis, and systemic 
lupus erythematosus are also susceptible to PCP (190) due to the administration of 
immunosuppressive drugs resulting in a decrease in CD4+ T cell number. Such drugs 
may include steroids, dactinomycin (a chemotherapeutic agent for cancers), and 
adalimumab (an anti-TNF-α drug). 
Pneumocystis has a high lung tropism; therefore nearly all Pneumocystis infections 
occur in the lung. However, some clinical reports have described cases of Pneumocystis 
infections in the thyroid (246), spleen (53), liver (53), and eyes (177). These 
extrapulmonary Pneumocystis infections usually occur on individuals with critically low 
immunity, such as patients at the very late stage of AIDS or cancer. 
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Clinical features of PCP include subtle onset of progressive dyspnea, nonproductive 
cough, and low-grade fever. Pneumothorax may develop when acute dyspnea and 
pleuritic chest pain appear. Lung auscultation is usually normal, but tachypnea and 
tachycardia normally occur (210). Chest radiography typically reveals bilateral perihilar 
interstitial infiltrates that become increasingly homogeneous and diffuse as PCP 
progresses (44). The mortality rate of PCP ranges from 10 to 20% in patient with AIDS 
and 30 to 60% in patients without AIDS (210). 
 
Pulmonary Pathology 
 
The histopathology of PCP is characterized by eosinophilic foamy exudates and 
Pneumocystis organisms in the alveoli (95). The protein-rich alveolar exudates contain 
abundant fibronectin, vitronectin, and surfactant proteins A and D (157, 255). 
Pneumocystis organisms are usually embedded in these exudates and attached on the 
alveolar epithelium in groups without cell invasion. Common pathological changes of 
PCP include a moderate level of interstitial fibrosis and alveolar septal thickening (124). 
Severe PCP is characterized by extensive pulmonary inflammation due to recruitment of 
inflammatory cells, particularly neutrophils and CD8+ T cells. Overwhelmed lung 
inflammation is more likely a direct cause of respiratory failure and death than the levels 
of Pneumocystis burden (118). 
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Epidemiology 
 
In the early 1980s, PCP rapidily became the leading opportunistic disease in 
HIV-infected patients (130), and approximately 75% of HIV-infected patients developed 
PCP during that time period (70). The incidence of PCP was significantly decreased due 
to PCP prophlaxis that began in 1989 (52) and highly active antiretrovial therapy 
(HAART) which started in 1992 (85). However, there is still a 0.4% PCP incidence rate 
among all population (144). 
Animal experiments showed that Pneumocystis organisms can be transmitted 
through the airborne route (80). However, it is still unknown whether Pneumocystis can 
survive outside mammalian hosts and remain infective, although there are evidences 
showing the presence of Pneumocystis DNA in natural environment (29). Clinical studies 
suggest that person-to-person spread is an important transmission route and individuals 
with normal immunity could be asymptomatic reservoirs of Pneumocystis (123, 140, 220). 
Serology studies of anti-Pneumocystis antibody in healthy infants reveal that the 
seropositive rate is 16% at the age of two months and gradually increases to 85% at the 
age of 20 months (219), showing that Pneumocystis infection is common in humans since 
early life and is usually asymptomatic unless immunocompromised.  
 Althogh Pneumocystis infection is usually asymptomatic in immunocompetent 
people, it may cause a low level of pulmonary inflammation in associated with other 
pulmonary diseases. Recenly studies have suggested the association between 
Pneumocystis residence and other lung diseases, such as chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF), and lung cancers. Patients with these lung diseases 
appear to have a higher rate of Pneumocystis colonization (145). 
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Diagnosis 
 
Pneumocystis organisms must be determined to be present in clinical samples to 
diagnose PCP. Bronchoalveolar lavage fluid (BALF) from bronchoscopy is the preferred 
diagnostic sample with a sensitivity ranging from 89 to 98% (78). Induced sputum or 
oropharyngeal wash are alternative samples; however the sensitivity and specificity of 
diagnosis using these samples are significantly lower than using BALF (236). 
Pneumocystis organisms in BALF, induced sputum, oropharyngeal wash, or lung 
tissue can be visualized with several staining methods. Pneumocystis trophs can be 
detected by using Papanicolaou, Gram-Weigert, or modified Wright Giemsa stains, and 
cysts can be visualized with Grocott-Gomori methenamine silver (GMS), cresyl echt 
violet, toluidine blue O, or calcofluor white fungal stains. GMS and Gram-Weigert are 
preferred staining methods for Pneumocystis diagnosis in clinical laboratories. In addition 
to conventional stains, immunofluorescent assay (IFA) using monoclonal antibodies 
against Pneumocystis organisms, is also commonly used. IFA is capable of detecting both 
trophic and cyst forms of Pneumocystis. While IFA is more sensitive than conventional 
stains, it is more expensive, time consuming, and less specific (174). 
Serum testing is being developed to help in the diagnosis of PCP. The levels of 
serum β-glucan, lactate dehydrogenase, KL-6 (a mucinous high-molecular weight 
glycoprotein, expressed on type II pneumonocytes), and C-reactive protein are changed 
during PCP. However, none of them is a specific marker for PCP. Among, these, β-glucan 
seems to be the most reliable serum marker for PCP (207). 
Advances in molecular biology continue to add new tools for diagnosis of PCP. 
Molecular diagnosis of PCP is performed by determining the presence of Pneumocystis 
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DNA in clinical specimens. The latest technology uses real-time PCR to detect 
Pneumocystis DHFR, DHPS, HSP70, or CDC2 genes (99). 
 
Prophylaxis and Therapy 
 
The first-line drug for treatment of PCP is a combination of trimethoprim and 
sulfamethoxazole (TMP/SMZ). TMP and SMZ inhibits Pneumocystis dihydrofolate 
reductase (DHFR) and dihydropteroate synthase (DHPS), respectively (77). TMP/SMZ is 
also commonly used for PCP prophylaxis. However, TMP/SMZ may cause adverse 
effects, such as rash, fever, and leucopenia (191). Approximately 60% of HIV(+) patients 
have TMP-SMZ hypersensitivity reactions (191). Furthermore, TMP/SMZ-resistant 
Pneumocystis strains have emerged (138). Molecular analyses revealed that a point 
mutation at amino acid 55 or 57 of the DHPS gene renders Pneumocystis organisms 
resistant to SMZ (77, 218). Mutations at amino acid codons 23, 60, 111, 171 of the 
Pneumocystis DHPS gene have also been reported, but their associations with SMZ 
resistance remains uncertain (180). DHPS mutants that are resistant to SMZ are also 
resistant to dapsone which is a sulfone drug and also targets DHPS (77). 
A number of studies have examined the effects of DHPS mutations on clinical 
outcomes such as treatment failure and death rate; however, the results from these studies 
are inconsistent. Some studies found that DHPS mutations are associated with increased 
treatment failure with TMP/SMZ or TMP/Dapsone (87) and increased death rates and 
that the death rate in patients infected with DHPS mutants is 3 fold higher than those 
infected with the wild-type (73). However, another study reported contradictory results 
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with no statistical differences between patients infected with wild-type and DHPS 
mutants in both treatment failure and death rate (150). 
The combination of clindamycin and primaquine is an alternative choice for PCP 
therapy. Clindamycin interferes with protein synthesis of the organism by preferentially 
binding to its ribosome (94). The target of primaquine remains unknown. 
Clindamycin/primaquine combination shows comparable efficacy to TMP/SMZ on mild 
to moderate PCP (211) and is an alternative regimen for patients who fail or cannot 
tolerate TMP/SMZ therapy. Another alternative drug for PCP is atovaquone, an analog of 
ubiquinone (coenzyme Q). It inhibits mitochondrial respiration in Pneumocystis by 
specifically binding to the ubiquinol oxidation site of the cytochrome bc1 complex. 
Atovaquone resistant Pneumocystis strains have also emerged, and mutations in the 
Pneumocystis cytochrome b gene have been shown to confer this resistance (89). 
Pentamidine is another PCP drug targeting mitochondrial function (253). Although it is 
commonly used to treat PCP, it is highly toxic and has significant adverse effects such as 
hypoglycemia and nephrotoxicity (155). 
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Chapter 2: Macrophage Receptors That Recognize Pneumocystis Organisms 
 
Pattern Recognition Receptor and Pathogen Associated Molecular Pattern 
 
The major surface antigens on Pneumocystis cell wall are mannoproteins and 
β-glucan, which are recognized as foreign antigens by immune cells. Since these 
molecules are shared among microorganisms, particularly fungi, these antigens are also 
named a pathogen associated molecular pattern (PAMP). Cell receptors recognizing a 
PAMP are termed pattern recognition receptors (PRRs). All Pneumocystis receptors that 
have been identified belong to PRRs. These receptors include mannose receptor (MR), 
Toll-like receptors (TLRs), dectin-1, and scavenger receptor (SR). The downstream 
signaling mediated by these receptors usually leads to activation of the transcription 
factor NF-κB which activates immune responses, such as phagocytosis and cytokine 
production. 
 
Mannose Receptor (MR) 
 
MR is a sugar binding protein and is classified as a C-type lectin. MR is primarily 
expressed on the surface of macrophages and dendritic cells. The extracellular region of 
MR contains an N-terminal cysteine-rich (CR) domain, a fibronectin type II (FNII) 
domain, and eight tandemly arranged C-type lectin-like carbohydrate recognition 
domains (CTLDs). The CR domain has sugar binding activity and binds to sulfated 
sugars terminating in SO4-3-Gal or SO4-3/4-GalNAc (209). The FNII domain binds to 
collagen I, II, III, and IV (149). The CTLDs bind to sugars terminating in mannose, 
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fructose, or N-acetyl glucosamine (209). The function of the MR cytoplasmic region is 
relatively unknown and no signaling motif has been identified. MR is also classified as a 
PRR and has been shown to bind P. carinii (51), Candida albicans (129), and 
Mycobacterium tuberculosis (84). The most well characterized ligand for MR on 
Pneumocystis organisms is the mannose-rich major surface glycoprotein (MSG) (158). 
One study found that soluble mannan (a ligand of MR) can reduce Pneumocystis 
β-glucan-induced TNF-α release (222), suggesting Pneumocystis β-glucan can also 
interact with MR, probably through the cooperation with TLR2 (205). 
The binding activity (97) and expression levels (96) of MR are found to be 
decreased in AMs during HIV infection, indicating that MR function is impaired during 
PCP. Pneumocystis is also shown to evade immune surveillance by stimulating AMs to 
increase the production of soluble MR thus decreasing phagocytosis (55). 
MR is involved in Pneumocystis-mediated AM activation, including NF-κB 
translocation, oxidant production, and cytokine release. Pneumocystis organisms 
stimulate AM NF-κB p50 and p65 nuclear translocation in a time- and MOI-dependent 
manner, and this activation is diminished by competitive inhibition of MR with mannan 
or siRNA (250). Likewise, Pneumocystis stimulated H2O2 burst is decreased by 63% 
when AMs are treated with the MR competitive inhibitor mannosyl-BSA (98). The 
release of chemotactic cytokine IL-8 from AMs after Pneumocystis stimulation is 
decreased after MR siRNA knockdown, and this Pneumocystis-mediated IL-8 production 
is dependent on coexpression of TLR2 (205). 
Although previous results have suggested the importance of the MR in host defense 
during Pneumocystis infection, a study using MR-knockout (MR-KO) mice found that 
deficiency of MR does not cause increased Pneumocystis susceptibility (203); this is 
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similar to the results found in MR-KO mice infected with Candida albicans (110). These 
results reveal that the role of the MR in host defense is dispensable and may be 
compensated by other signaling pathways. 
 
Toll-Like Receptor (TLR) 
 
In 1996, a protein termed Toll was found with antifungal activity in Drosophila 
(112). A human homologue of Drosophila Toll protein (now known as TLR4) was later 
found to mediate immune signaling and responses, including NF-κB activation, the 
production of inflammatory cytokines IL-1, IL-6, IL-8, and the expression of the 
costimulatory molecule B7.1 for naive T cell activation (132). A number of human 
membrane proteins sharing structural similarity to Toll have been identified and classified 
into a family named Toll-like receptor (TLR) (181). The progress in genome projects has 
led to the identification of at least 10 TLRs in vertebrates (59). 
TLRs are type I transmembrane glycoproteins (59). The extracellular domains of 
TLRs have leucine-rich repeat (LRR) modules and are responsible for the binding of 
PAMPs. For example, lipoproteins or lipopeptides are recognized by TLR2; 
lipopolysaccharide, a major component on Gram(-) bacteria, is recognized by TLR4; viral 
double-stranded RNA is recognized by TLR3; bacterial flagellin is recognized by TLR5; 
single-stranded RNA virus is recognized by TLR7 or TLR8; and microbial unmethylated 
CpG DNA is recognized by TLR9 (212). The cytoplasmic domain of TLRs shares high 
similarity to that of IL-1 receptor family and is referred to as Toll/IL-1 receptor (TIR) 
domain which is composed of 150 amino acid residues. Binding of ligands induces the 
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dimerization of TLRs and then recruits adaptor proteins to the TIR domains to initiate 
intracellular signaling. 
The adaptor proteins for TLR signaling include MyD88, MAL, TRIF, TRAM, and 
SARM. These TLR adaptors also contain TIR domains (156), and the TIR-TIR 
interactions between receptor-receptor, receptor-adaptor, and adaptor-adaptor play a 
critical role in TLR signalings (163). MyD88 is the most commonly used TLR adaptor by 
TLRs. MyD88 plays a critical role in the immune responses against microbial infections 
as MyD88-deficient mice produce less cytokines and are more susceptible to microbial 
infections (156). 
MyD88 is composed of two major domains: a TIR domain at the C-terminal end and 
a death domain at the N-terminal end. The death domain of MyD88 interacts with the 
death domain of IL-1 receptor-associated kinase 4 (IRAK4) which recruits and 
phosphorylates IRAK1, leading to its activation (201). Activated IRAK1 in turn activates 
tumour necrosis factor receptor-associated factor 6 (TRAF6). Activated TRAF6 forms a 
complex with transforming growth factor-β-activated kinase-1 (TAK1) via the 
associations with the proteins TAK1 binding protein 1 (TAB1) and TAB2. Formation of 
TRAF6/TAK1 complex leads to the activation of TAK-1 (154). TAK-1 then 
phosphorylates the inhibitory κB (IκB) kinase complex, leading to NF-κB activation. 
Transcription factor NF-κB plays a central role in immune responses by controlling the 
production of a variety of cytokines and chemokines. 
TLR2 recognizes the most numerous ligands among all TLRs. Parts of this diversity 
are due to its ability to form heterodimers with many other receptors, such as TLR1, 
TLR6, MR (205), and Dectin-1 (58). Ligands that are recognized by TLR2 include 
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zymosan on fungi, peptidoglycan and lipoteichoic acid on Gram(+) bacteria, 
lipoarabinomannan on Mycobacteria, and lipoproteins on most organisms (59). 
TLR2 mediates immune reactions in response to Pneumocystis infection. An in vivo 
study shows that TLR2 is involved in Pneumocystis-induced production of the 
proinflammatory cytokine tumor necrosis factor α (TNF-α) and chemokine macrophage 
inflammatory protein 2 (MIP-2) (247). In vivo study of Pneumocystis-infection in 
TLR2-deficient mice shows less inflammation, TNF-α production, and NF-κB activation 
than in wild-type mice with PCP. These results confirm the inflammatory role of TLR2 in 
PCP. However, TLR2-deficient mice show increased severity in symptoms and organism 
burden and decreased levels of inducible nitric oxide synthase, NADPH oxidase p47phox, 
amd nitric oxide in the lungs, indicating the important roles of TLR2 in host defense 
against Pneumocystis (234). In addition, TLR2 has also been shown to mediate the 
release of IL-8 from macrophages when coexpressed with MR during Pneumocystis 
challenge (205). 
TLR4 has also been shown to mediate host responses during PCP. TLR4-deficient 
mice showed exacerbated pulmonary damage compared to wild type mice with PCP. 
TLR4-deficiency results in increases in the levels of TNF-α and IL-6, but decreases in 
those of IL-10, IL-12, and MIP-2 in response to Pneumocystis infection. TLR4 seems to 
play no role in controlling organism burden since the numbers of Pneumocystis 
organisms were nearly the same in TLR4-deficient and wild type mice with PCP (46). 
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Dectin-1 
 
Dectin-1 (also known as C-type lectin domain family 7 member A, CLEC7A) is a 
33 kDa type II transmembrane protein. The N-terminal domain of Dectin-1 is located in 
the cytoplasmic region. It has a motif similar to the short immunoreceptor 
tyrosinase-based activation motif (ITAM) and works as a signaling tail. The C-terminal 
end of dectin-1 is exposed to extracellular space for antigen binding by the carbohydrate 
recognition domain (CRD). Unlike most C-type lectin members, Dectin-1 binds to 
ligands in a calcium-independent manner. Dectin-1 is predominantly expressed on the 
surface of myeloid cells, including macrophages, monocytes, and neutrophils. Dendritic 
cells and some T cells also express Dectin-1, but at lower levels. AMs have been shown 
to express the highest levels of surface dectin-1 (208). 
In 2001, Dectin-1 was first reported as a receptor for β-1,3-glucan (24), a major 
component on fungal and some bacterial cell walls. Engagement of Dectin-1 by β-glucan 
induces a variety of cellular responses including endocytosis, phagocytosis, reactive 
oxygen species (ROS) production, and the synthesis of cytokines and chemokines, such 
as TNF, IL-6, IL-10, IL-23, and CXCL2 (23). Dectin-1 directs intracellular signaling 
alone or in cooperation with other membrane receptors, such as TLR4 (58) or DC-SIGN 
(217). This feature is cell-type dependent. For example, Dectin-1 signaling alone induces 
TNF production in dendritic cells (111), but this response requires TLR2 costimulation in 
macrophages (45). Evidence has suggested that this difference is, at least partly, caused 
by cytokines, such as GM-CSF and IFN-γ (64). 
Dectin-1 is the first non-TLR PRR found to be capable of inducing its own 
intracellular signaling (23). The most well studied Dectin-1 signaling is through the 
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canonical NF-κB activation pathway. Dectin-1 signaling begins from the phosphorylation 
of its cytoplasmic ITAM-like motif by spleen tyrosine kinase (Syk) (215). Biding of Sky 
to the target tyrosine residues on Dectin-1 is mediated by the two SH2 domains on Syk. 
Although both Syk SH2 domains are involved in Dectin-1 phosphorylation, only the 
proximal tyrosine is required for signaling (56). Caspase recruitment domain 9 (CARD9) 
is an essential downstream adaptor protein for Syk-coupled receptors. CARD9 assembles 
with B-cell CLL/lymphoma 10 (BCL10), mucosa associated lymphoid tissue lymphoma 
translocation 1 (MALT1), and TNF receptor associated factor 6 (TRAF6). TRAF6 
interacts with UBE2N/UBC13 and UBE2V1/UEV1A which ubiquitinate IκB kinase 
(IKK). Activated IKK phosphorylates IκB and results in IκB degradation. NF-κB released 
from IκB then translocates to the nucleus and activates gene expressions. Dectin-1 
signaling through Syk-independent pathway (67), non-canonical NF-κB activation 
pathway (67), CARD9-independent pathway (64), or Nuclear factor of activated T-cells 
(NFAT) activation (65) has also been reported. Dectin-1 appears to be the first PRR found 
to activate non-canonical NF-κB pathway (67). 
Dectin-1 also induces intracellular signals via collobration with other membrane 
receptors. In macrophages, TLR2 plays a necessary role in Dectin-1 signaling in the 
induction of TNF production (45). This was the first demonstration of interactions 
between a TLR and a non-TLR receptor (23). 
In 2003, Dectin-1 was first shown to be a phagocytosis receptor for Pneumocystis 
(193), mediating organism killing and the production of MIP-2 in response to 
Pneumocystis challenge in vitro. Another study found that anti-Dectin-1 antibody blocked 
the production of TNF-α in dendritic cells challenged with purified Pneumocystis 
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β-glucan (28). These results demonstrated the role of Dectin-1 in organism recognization 
and clearance and cytokine productions in response to Pneumocystis infection. 
Taken the property of β-glucan/Dectin-1 binding, a Dectin-1-Fc fusion protein was 
generated and used as an immunomodulating molecule against Pneumocystis. 
Pneumocystis organisms pre-opsonized with Dectin-1-Fc are more readily phagocytosed 
and killed by AMs (178). SCID mice transduced by a Dectin-1-Fc-containing adenovirus 
have decreased Pneumocystis burden and pulmonary damages (178). 
Dectin-1-deficient mice were used to clarify the role of Dectin-1 in defense against 
Pneumocystis infection. These mice had increased Pneumocystis burden and decreased 
ROS levels. However, the levels of cytokine TNF-α and IL-12 were not significantly 
changed, suggesting the existence of a compensatory mechanism for Dectin-1 in the 
induction of cytokine productions during PCP. (184). 
 
Scavenger Receptor (SR) 
 
SR is a membrane protein principally expressed on myeloid cells such as 
macrophages and dendritic cells. SRs can bind to a variety of ligands such oxidized or 
acetylated low density lipoproteins, lipopolysaccharide on Gram(-) bacteria, lipoteichoic 
acid on Gram(+) bacteria, intracellular bacteria, and CpG-rich DNA (165). SRs mediate 
the internalization and cleaning (scavenging) of these exogenous molecules or organisms. 
There are three categories of SRs: classes A, B, and C, differentiated by their structural 
characteristics. Class SR A (SR-A) is mainly expressed on macrophages and plays a 
major role in inflammatory responses. SR-A knockout mice are more susceptible to 
bacterial infections (200), showing the role of SR in the deference against microbial 
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infections. However, SR-A knockout mice infected with Pneumocystis showed decreased 
organism burden compared to wild-type mice; this is likely due to elevated numbers of 
activated CD4+ cells in SR-A deficient micc. SR-A deficiency also caused increased 
productions of TNF-α, IL-12, and IL-18 during PCP, but AM phagocytosis was not 
affected. In contrast to its role in bacterial infections, SR-A seems to be a negative 
inflammatory regulator during PCP (76). 
 
NF-κB 
 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a complex 
of proteins acting as a transcription factor in nearly all cell types. NF-κB is involved in 
cellular responses to various stimuli such as cytokines, microorganism, viruses, free 
radicals, UV, and hypoxia. 
There are five NF-κB family members in mammalian cells: NF-κB1, NF-κB2, RelA 
(p65), RelB, and c-Rel. All members in the NF-κB family share a Rel homology domain 
(RHD) in their N-terminus. The Rel subfamily of NF-κB, including RelA, RelB, and 
c-Rel, has a transactivation domain (TAD) in their C-termini. In contrast, the C-termini of 
immature NF-κB1 (p105) and NF-κB2 (p100) are composed of ankyrin repeats which 
have transrepression activity. p105 and p100 are processed by the ubiquitin/proteasome 
pathway which selectively degrads the C-terminal ankyrin repeats to form mature 
NF-κB1 (p50) and NF-κB2 (p52) subunit. A mature NF-κB complex is a homodimer or a 
heterodimers of these proteins. Since the NF-κB subunits p50 and p52 do not contain 
TAD in their C-terminals, the homodimer or heterodimer of p50 and p52 do not activate 
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gene expression. Therefore, p50 and p52 must dimerize with other TAD-containing 
subunit to form a functional NF-κB transcription complex. 
NF-κB is one type of the “rapid-acting” transcription factors which are mostly 
present in an inactive state in cells; when receiving stimulus, NF-κB can be quickly 
activated without new NF-κB protein synthesis. Without stimulation, NF-κB is normally 
retained in the cytoplasmic area by inhibitors of NF-κB (IκBs). Activation of NF-κB is 
typically initiated from the phosphorylation of IκB by IKK, which consequently results in 
IκB degradation. Released NF-κB is then translocated to the nucleus to bind to promoters 
to activate gene expression. 
NF-κB is commonly activated in response to infections and is a key transcription 
factor in immune responses. Nearly all Pneumocystis receptor signaling pathways 
converge at NF-κB, including TLR (247), Dectin-1 (50), MR (250), and SR (113). 
 
NFAT 
 
Nuclear factor of activated T-cells (NFAT) is a family of transcription factors 
involved in immune response and is commonly expressed in immune cells. There are five 
members in the NFAT family: NFATc1, NFATc2, NFATc3, NFATc4, and NFAT5 (40). The 
activation of NFATc1, NFATc2, NFATc3, and NFATc4 is regulated by the calcium sensor 
protein calmodulin. Calmodulin activates a serine/threonine phosphatase termed 
calcineurin. Activated calcineurin rapidly dephosphorylates the serine rich region and 
serine-proline repeats in the amino termini of NFAT proteins, resulting in a 
conformational change. Dephosphorylated NFAT exposes a nuclear localization signal 
which leads NFAT to the nucleus to active gene expression by acting as a transcription 
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factor. The nuclear translocation of NFAT is inhibited by kinases present in cytoplasm 
and nucleus. NFAT alone has weak DNA binding ability; therefore, cooperation with 
other nuclear resident transcription factors is required for effective binding to DNA by 
NFAT (125). NFAT has recently reported to be activated by Candida albicans or zymosan 
through Dectin-1 signaling, suggesting that NFAT may be a transcription factor involved 
in immune responses during PCP. 
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Chapter 3: Host Responses during PCP 
 
The host immune response during PCP involves complex interactions among 
inflammatory cells, including lymphocytes (CD4+ T cells, CD8+ T cells, and B cells), 
neutrophils, and AMs. These interactions are communicated by complex cytokine and 
chemokine networks, particularly IFN-γ and TNF-α. 
 
CD4+ T Lymphocytes 
 
CD4+ T cells play a crucial role in host defense against PCP, as patients with CD4+ 
cells lower than 200 per microliter of the peripheral blood have a higher risk of PCP. 
CD4+ T cells can be classified into three categories by their functions: effector T cells 
secrete cytokines to activate or recruit other immune cells; memory T cells retain the 
same antigen affinity as originally activated T cell for a rapid response during 
reinfections; regulatory T cells are responsible for negative regulation of immune 
responses. CD4+ cells mainly secret IFN-γ and IL-2 to activate macrophage and promote 
the proliferation of CD8+ cells. Insufficient IFN-γ levels have been shown to be a 
consequence of low CD4+ cell number and contribute to the immunosuppressive status to 
allow Pneumocystis infection (92). 
 
CD8+ T Lymphocytes 
 
CD8+ T cells are substantially infiltrated into the lung in the severe stage of PCP. 
The major type of cytokine secreted by CD8+ T cells during PCP is IFN-γ which 
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activates other immune cells such as AMs. The role of CD8+ cell in the disease progress 
of PCP is controversial. CD8+ cells have been shown to play a role in host defense 
against this infection, as depletion of both CD8+ and CD4+ cells in animals results in a 
more severe PCP than those with depletion of only CD4+ cells (15). An increase in the 
number of CD8+ cells can lead to PCP recovery (92). These results demonstrate the 
protective role of CD8+ cells in the host defense against PCP (194). However, CD8 cells 
have also been shown to be responsible for the pulmonary damage during PCP, as 
Pneumocystis-infected SCID mice reconstituted with wild-type CD8 T cells showed more 
severe lung injury than those that were not immune reconstituted (133). This type of 
damage has been shown to be dependent on MHC class I (133). This CD8+ cells 
mediated pulmonary injury has been proposed to be the direct cause of impaired gas 
exchange and respiratory failure in PCP, since respiratory impairment and death seem to 
be more closely related to the extent of pulmonary inflammation than to the 
Pneumocystis burden (118). 
 
B Lymphocytes 
 
B cells are involved in humoral immunity. The presence of B cell is very important 
in host defense against PCP since B cell-deficient mice are naturally susceptible to 
Pneumocystis infection (122). This susceptibility is due to the requirement of B cells in 
the generation of effector and memory CD4+ T cells, which are the key cell types against 
PCP as described above. 
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Neutrophils 
 
Neutrophils are largely recruited into the lungs in an advanced stage of PCP. The 
main function of neutrophils is to perform non-specific phagocytosis and release 
microorganism-killing materials such as proteases and oxidants. The recruitment of 
neutrophils is mediated by a potent neutrophil chemoattractant IL-8, whose levels in 
BALF were reported to be a good predictor of severe respiratory compromise and death 
in patients with PCP (20). Neutrophils were thought to be responsible for the pulmonary 
injury during PCP due to its potent protease and oxidative activity. However, a recent 
study using neutrophil-depleted mice model found that pulmonary damage caused by 
PCP is independent of neutrophils, but is highly associated with CD8+ T cells (204). 
 
Alveolar Macrophages (AMs) 
 
AM is differentiated from its precursor cell monocyte in the blood. When an 
infection occurs in the lung, monocytes are recruited from the blood by chemokines, such 
as monocyte chemoattractant protein-1 (MCP-1). There are several types of macropahges 
in the lung, including alveolar, interstitial, intravascular and airway macrophages. AMs 
are the most predominant population. The maturation of AMs is mainly regulated by the 
granulocyte macrophage colony-stimulating factor (GM-CSF). 
AMs produce TNF-α and MIP2 during PCP. Production of these cytokines are 
induced by Pneumocystis β-glucan (68, 107) with the assistance of glucan binding 
proteins vitronectin and fibronectin (221). Membrane receptor TLR2, but not TLR4, and 
transcription factor NF-κB are involved in the production of these cytokines (247).   
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AM is the major cell type responsible for the clearance of Pneumocystis organisms 
(117). Phagocytosis is initiated when Pneumocystis organisms bind to membrane 
receptors on AMs. The organisms are then internalized into AMs to form a phagosome 
which can fuse with lysosome to become a phagolysosome. The organisms are killed by 
free radicals and degraded by various proteolytic enzymes in phagolysosome. As 
described above, some AM receptors have been found to bind Pneumocystis; however, 
not all of them are involved in phagocytosis. MR (51) and Dectin-1 (193) have the ability 
to mediate AM phagocytosis of Pneumocystis organisms, whereas TLR2 (248), TLR4 
(46), and SR (76) are not known to trigger phagocytosis. 
Although being an important organism clearance process, AM phagocytic activity is 
decreased during PCP. The downregulation of MR (96) and transcription factor GATA-2 
(106) have been shown to cause defects in AM phagocytosis. 
In addition to reduced phagocytosis, the number of AMs is decreased during PCP in 
both humans (54) and animals (101, 105) due to the increased rate of apoptosis (103) and 
decreased GM-CSF production (104), which may cause less maturation of macrophages 
from monocytes in the lung. Inhibition of AM apoptosis by treating with caspase-9 
inhibitor significantly prolonges animal survival, increases AM number and phagocytic 
activity, and decreases organism burden in rodents with PCP, demonstrating that AM 
apoptosis correlates with the disease progress of PCP (103). 
 
Alveolar Epithelial Cells 
 
There are two types of alveolar epithelial cells (also know as pneumocytes). Type I 
alveolar epithelial cells (also called squamous alveolar cells) are the main cell type that 
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forms the structure of alveolar walls. Type II alveolar epithelial cells (also called great 
alveolar cells) secrete surfactant proteins to lower the surface tension in the lung, 
allowing the alveolar membrane to separate and increasing the capacity of gas exchange. 
Pneumocystis infects type I alveolar epithelial cells. This infection is facilitated by 
some host matrix proteins such as fibronectin and vitronectin which allow tight adherence 
of Pneumocystis to type I alveolar epithelial cells (228). Fibronectin and vitronectin bind 
to both Pneumocystis and the integrin receptors on the alveolar epithelium to enhance 
organism and host cell interactions (119). Histopathology analysis showed that 
Pneumocystis-infected epithelial cells are vacuolated and eroded (19). An in vitro study 
showed that Pneumocystis dose not cause any disruptions in the metabolism, structure, 
and barrier function of epithelial cells and suggested that inflammatory cells are 
responsible for the damage of epithelial cells during Pneumocystis infection (16). Another 
study showed that Pneumocystis inhibits cyclin-dependent kinase (CDK) activity in lung 
epithelial cells; this may serve another mechanism causing epithelial cell damages (116). 
Although not a major source of chemokines and cytokines, alveolar epithelial cells 
also produce TNF-α (50), MIP2 (50), IL-8 (18), IL-6 (172), and MCP-1 (18) in response 
to Pneumocystis infection. Activated NF-κB is involved in the production of TNF-α and 
MIP2 (50, 249), and JNK participates in the induction of MCP-1 production (233). 
 
Interferon-γ (IFN-γ) 
 
IFN-γ is a cytokine predominately secreted by CD4+ and CD8+ T cells, and its main 
target is macrophages. IFN-γ activates phagocytosis, cytokine productions, antigen 
presentation, and lysozyme activity in macrophages. Transfer of IFN-γ gene by 
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adenovirus-mediated gene delivery (92) or aerosolized recombinant IFN-γ protein (14) 
showed significantly improved organism clearance, demonstrating the essential role of 
IFN-γ against Pneumocystis infection. 
 
Tumor Necrosis Factor α (TNF-α) 
 
TNF-α is a cytokine mainly produced by activated AMs in Pneumocystis-infected 
lungs. It recruits other inflammatory cells, including neutrophils, lymphocytes, and 
monocytes in order to establish an optimal environment for organism clearance. TNF-α 
also induces the generation of other cytokines and chemokines, particularly IFN-γ from T 
cells and IL-8 from lung epithelial cells. TNF-α has been demonstrated to play a critical 
role in the immune response against Pneumocystis infection, as the clearance of 
Pneumocystis is significantly reduced when TNF-α is neutralized by antibodies (33) or 
inhibitors (93). Although playing an important role in the clearance of Pneumocystis 
organisms, TNF-α-mediated inflammatory response is considered a major cause of lung 
damages during PCP (175). Several substances have been found to induce TNF-α 
production during PCP, including Pneumocystis cell wall components β-glucan (75) and 
MSG (17) and IFN-γ (48). 
 
Macrophage Inflammatory Protein 2 (MIP-2) 
 
MIP-2 is a chemokine produced by AMs and lung epithelial cells. The main function 
of MIP-2 during PCP is to recruit neutrophils into the lungs. The production of MIP-2 can 
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be induced by isolated Pneumocystis β-glucan (68). Pneumocystis mediated MIP-2 
production has been shown to be mediated by TLR2 (247) and TLR4 (46) signaling. 
 
Surfactant Protein (SP) 
 
SP is a type of protein secreted by alveolar epithelial cells and reduces the surface 
tension at the alveolar air spaces. SP also modulates immune responses in the defense of 
Pneumocystis infection. Different types of SPs are formed as foamy exudates in the 
alveoli in the lungs with PCP. The expression levels of SP-A and SP-D are increased, 
whereas those of SP-B and SP-C are decreased during PCP (6). 
SP-A enhances the binding between Pneumocystis and AMs (239). MSG has been 
shown to be a ligand of SP-A (255). SP-A-deficient mice with PCP showed enhanced 
lung injury and delayed organism clearance due to attenuated cytokine and oxidative 
responses (5). SP-D mediates aggregation of Pneumocystis and impairs AM phagocytosis 
(245). SP-D-overexpressing mice with PCP showed markedly increased Pneumocystis 
burden (225). This surfactant mediated pathology seems to be a result of the 
inflammatory responses, rather than a direct effect from Pneumocystis organisms (240). 
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Chapter 4: Polyamines and Macrophage Apoptosis 
 
Polyamines and Their Metabolism Enzymes 
 
Polyamines are polycationic amines present in all cells and are involved in the 
regulation of many cellular functions, such as cell cycle progression (160), differentiation 
(223), oncogenesis (61), and apoptosis (187). The most common biological polyamines 
are putrescine, spermidine, and spermine (Fig. 1). Polyamine metabolism pathway is 
shown in Fig. 2. Ornithine decarboxylase (ODC) is the rate-limiting enzyme in 
polyamine biosyntheses. ODC decarboxylates ornithine to putrescine which is converted 
to spermidine by spermidine synthase (SRM). Spermidine is then converted to spermine 
by spermine synthase (SMS). Polyamine catabolism is activated in response to the 
excessive intracellular polyamine levels. This catabolism is mediated by 
spermidine/spermine N1-acetyltransferase (SSAT), polyamine oxidase (PAO), and 
spermine oxidase (SMO). SSAT acetylates spermidine to N1-acetylspermidine and 
spermine to N1-acetylspermine. N1-acetylspermine and N1-acetylspermidine are 
excreted from cells or converted back to spermidine and putrescine, respectively by PAO, 
while spermine can be back converted to spermidine by SMO. A mechanism which 
controls the level of ODC is degradation. ODC antizyme (OAZ) targets ODC to the 26s 
proteasome for degradation, whereas antizyme inhibitor (AZI) inhibits this degradation 
by binding to OAZ. 
Intracellular polyamine homeostasis is critical for normal cellular functions and cell 
survival. Several polyamine regulatory mechanisms exist in cells in response to altered 
intracellular polyamine levels. When cellular polyamine levels are high, the mechanisms 
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of increased ODC degradation, polyamine catabolism, and polyamine export are 
activated. In contrast, mechanisms of increased ODC synthesis and polyamine import and 
decreased ODC degradation and polyamine catabolism are activated in response to 
insufficient polyamine levels. 
 
Ornithine Decarboxylase (ODC) 
 
ODC, the key enzyme for polyamine biosynthesis, is crucial for cell survival as 
homozygous ODC knockout mice are lethal (166). In mammalian cells, ODC is the only 
source for cells to acquire putrescine from de novo biosynthesis. However, ODC is 
abscent in some microorganisms and plants due to the existence of a similar enzyme 
arginine decarboxylase which can convert arginine to putrescine (91). A functional ODC 
protein is a homodimer with active site between the N-terminal domain of one subunit 
and the C-terminal domain of the other (3). Pyridoxal phosphate (PLP) is an essential 
cofactor for ODC activity. In mammalian cells, ODC tightly regulates intracellular 
polyamine levels to maintain polyamine homeostasis. ODC activity is regulated at the 
levels of transcription, translation, and protein degradation. 
The promoter of the ODC gene contains many regulatory elements, including cAMP 
response element, CAAT and LSF motifs, AP-1 and AP-2 sites, GC-rich Sp1 binding sites, 
and TATA box (176, 254). The oncogene Myc is a well defined transcription factor which 
binds to ODC promoter and activates its expression (161). ODC promoter contains two E 
boxes with CACGTG sequences conforming to the canonical CAYGTG sequence to 
which Myc binds. ODC activity is also regulated by protein degradation. The degradation 
of mammalian ODC take places in the 26S proteasome with a very short turnover rate 
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(T1/2 = 10-20 min). This rapid turnover is determined by its C-terminal 37 residues (251), 
which is absent in the ODC of Trypanosoma cruzi. Therefore, Trypanosoma cruzi ODC is 
much more stable. 
 
ODC Antizyme (OAZ) 
 
ODC degradation is mediated by OAZ which non-covalently binds to the PLP 
binding site on ODC monomer to form a heterodimer. This complex is directed to the 26S 
proteosome for an ATP-dependent but ubiquitin-independent degradation, resulting in 
decreased ODC and polyamine levels (71). OAZ only enhances the interaction between 
ODC and proteasome; it does not increase the proteasome processing rate (252). At least 
three forms of mammalian OAZ have been identified; all of them inhibit ODC activity 
but with different tissue distribution and expression levels (127). 
The levels of OAZ are regulated by polyamine levels (131, 162); suriprisingly, ODC 
is not involved in this regulaton (57). The expression of OAZ is translationally regulated 
by the levels of polyamines, particularily spermidine and spermine. OAZ transcript has 
two overlapping open reading frames. When polyamine levels are low, OAZ translation 
terminates at the stop codon located at 65 codons downstream of the translation initiation 
site, producing a nonfunctional OAZ protein. When polyamine levels are high, a 
translational frameshifting occurs and causes the paused ribosome to read through the 
first stop codon to produce a functional OAZ (131). OAZ is the only known mammalian 
protein whose translation is influenced by polyamines in this manner. Polyamine levels 
also regulate OAZ degradation as the process of an ubiquitin-dependent OAZ 
degradation in the 26S proteosome is inhibited by the addition of polyamines (162). 
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Antizyme Inhibitor (AZI) 
 
AZI is a protein with high structural similarity to ODC, but AZI has no 
decarboxylase activity (147). It has higher OAZ binding activity than ODC; therefore, 
AZI releases ODC from the ODC/OAZ complex by competitive binding, leading to 
decreased ODC degradation and increased polyamine synthesis (147). AZI is capable of 
disrupting the binding of ODC to all OAZ isoforms that have been identified (128). AZI 
turns over very rapidly (T1/2 < 30 min); the process of AZI degradation occurs in the 26S 
proteasome and is ubiquitin-dependent (21). AZI is tightly associated with cell growth; it 
is quickly synthesized when cells are stimulated to grow (153), and knockdown of AZI 
results in growth inhibition (35). 
 
Spermidine/Spermine N1-Acetyltransferase (SSAT) 
 
SSAT mediates polyamine catabolism in response to increased polyamine levels. 
SSAT acetylates spermidine and spermine to N1-spermidine and N1-spermine, 
respectively. These acetylated polyamines are normally excreted from cells to urine. 
SSAT activity is normally present at a very low level in resting cells and is induced in 
response to increased polyamine levels. Polyamines regulate SSAT activity at multiple 
levels, including transcription, mRNA stability, translation, and protein degradation. 
Transcriptional activation of SSAT is mediated by the polyamine responsive element 
(PRE) with the sequence TATGACTAA in the SSAT promoter (237). PRE allows the 
binding of the transcription factor NF-E2-related factor 2 (Nrf-2) which partners with 
polyamine modulated factor 1 (PMF-1) to activate SSAT expression (235). 
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SSAT mRNA stability is regulated by alternative splicing. SSAT pre-mRNA has an 
extra 100 bp exon containing multiple premature termination codons between exon 3 and 
4, leading to nonsense-mediated mRNA decay (81) or a truncated unfunctional SSAT (90). 
The function of this aberrant mRNA variant under normal physiological condition is 
uncertain, but it has been shown to accumulate in response to the simulation by X-rays 
(142), viruses (152), and hypoxia (90). Polyamine mediated SSAT translation is shown by 
the observation that a substantial proportion of SSAT mRNA is moved to the 
polyribosomes when polyamine is added (164). 
The degradation of SSAT takes place in the 26S proteasome after polyubiquitination. 
SSAT normally has a rapid turnover rate with a half-life of 20 min. This rapid 
degradation is mediated by the C-termial MATEE motif (38). However, the half-life of 
SSAT can be as long as 12 hr in the presence of additional polyamines. This is due to the 
interuption of SSAT polyubiquitination mediated by polyamines (37). 
 
Polyamine oxidase (PAO) and Spermine Oxidase (SMO) 
 
In addition to SSAT, PAO and SMO also participate in polyamine catabolism. PAO 
converts N1-acetylspermine to spermidine and N1-acetylspermidine to putrescine. SMO 
catalyzes sperimine to become spermidine. PAO and SMO are very similar enzymes but 
with different substrate preference; in fact, PAO has some SMO activity and vise versa. 
At least four PAO isozymes have been cloned and characterized; these isozymes are 
encoded by the same gene which is transcribed to different mRNA splice variants (148). 
PAO/SMO is present in cytosolic compartment and peroxisome in all vertebrate 
cells. PAO/SMO activity is dependent on the presence of the cofactor 
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flavin-adenin-dinucleotide (FAD). The catabolic reaction of PAO/SMO produces H2O2, 
aminodialdehyde, and ammonia. H2O2 is a potent oxidant with strong cytotoxicity, and 
activation of PAO has been shown to induce macrophages to undergo apoptosis (32). 
N1,N4-bis(2,3-butadienyl)-1,4-butanediamine (MDL 72527) is an irreversible 
inhibitor of PAO. It inactivates PAO at a micromolar concentration in a time dependent 
manner in vitro and in vivo. MDL 72527 efficiently inhibits PAO and partially inhibit 
SMO without affecting other oxidases in cells and other enzymes in polyamine 
metabolism. A concentration of 200 μM of MDL-72527 has been shown to inhibit 
oxidation of PAO substrate N1-acetylspermine by 84% and SMO substrate spermine by 
about 50% (22). 
 
Polyamine Transport 
 
Mammalian polyamine transport system has long been a research subject of great 
interest but limited progress, despite having the knowledge of polyamine transporters in 
prokaryotic cells and yeast. In E. coli, the PotF/G/H/I ATP-binding cassette is responsible 
for putrescine uptake, PotE mediates both the uptake and excretion of putrescine, and the 
PotA/B/C/D ATP-binding cassette preferentially transports spermidine into the cell (82). 
In S. cerevisiae, uptake of polyamines have been shown to be mediated by a number of 
amino acid transporters, including DUR3 (213), SAM3 (213), AGP2 (4), and Gap1p 
(214). Yeast mutants deficient in any of these proteins showed decreased polyamine 
uptake. 
The diamine exporter (DAX) is the only polyamine transporter found in mammalian 
cells so far (242); however, it only exports acetylated polyamines (242).  There is no 
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evidence to suggest that it also works on other polyamines or acts as a polyamine 
importer. 
In addition to the modulation of ODC degradation, OAZ and AZI were surprisingly 
found to regulate polyamine transport. OAZ decreases polyamine import (143), whereas 
AZI overexpression increases polyamine import (88). The mechanisms of OAZ- and 
AZI-mediated polyamine transport are still unknown. 
 
α-difluoromethylornithine (DFMO) 
 
The compound DFMO was first demonstrated to potently inhibit ODC activity and 
suppress tumor cell growth in the 1970s (126). DFMO inhibits ODC activity by binding 
to its active site at Lys 69 and Lys 360. DFMO is cleaved by ODC, but the digested 
products stay bound to the active site and irreversibly render the enzyme inactive (173). 
DFMO is the best known and most effective inhibitor of polyamine biosynthesis, and is 
the first anticancer drug targeting ODC. In vitro treatment of cells with DFMO has been 
shown to effectively deplete putrescine and spermidine, but spermine level is much less 
affected (60). DFMO inhibits cell growth by arresting cells at the G1 phase of the cell 
cycle (179). Although blocking polyamine synthesis has been shown to inhibit tumor 
growth in vitro and in animal models, clinical trials on anticancer activity of DFMO have 
not been successful. This may be due to compensatory increases in polyamine uptake (1), 
incomplete deprivation of spermine, or retroconversion of spermine to spermidine and 
putrescine (60). However, DFMO is still considered a potent agent to prevent cancer 
development as there have been some successes in animal and human clinical trials for 
tumor chemoprevention (139). 
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In 1980, DFMO therapy on rats with trypanosomiasis surprisingly showed 
significant success (10). Subsequently, successful human clinical trials made it an 
effective treatment regime for this disease (141) and a US FDA approved drug for 
sleeping sickness in 1990 (151). The selective toxicity of DFMO to Trypanosoma is due 
to the huge difference in the half-life of Trypanosoma (more than 10 hr) and mammalian 
ODC (10-20 min). In addition, Trypanosoma does not have a mechanism such as uptake 
of exogenous polyamines to compensate the loss of polyamines due to DFMO treatment 
(11). DFMO has also been shown to have activity against Plasmodium falciparum (146), 
Giardia lamblia (63), Eimeria tenella (69), and Trichomonas vaginalis (244). DFMO has 
been used to treat PCP in humans, but only 57% of PCP patients (40 of 70) responded to 
the treatment (192). This partial success suggests that polyamine metabolism is a viable 
target against PCP, but targeting polyamine synthesis alone may not be sufficient. 
 
Polyamine and Apoptosis 
 
An increasing body of evidence indicates that polyamines can induce apoptosis (also 
called the programmed cell death) (171, 187, 189). It is a type of cell death process 
involving cell shrinkage, chromatin condensation in the periphery of the nucleus, cell 
membrane blebbing, and cleavage of DNA into multiple fragments of approximately 180 
bp. The apoptotic cells eventually break up into many membrane-bound apoptotic bodies, 
which are then phagocytosed by neighboring phagocytes. The activation of apoptosis can 
be classified into two different pathways: receptor- (extrinsic) and mitochondria-mediated 
(intrinsic). Receptor-mediated apoptosis is initiated by the binding of Fas-L or TNF-α to 
their receptors and subsequently activates caspase-8, caspase-10, and caspase-3 by a 
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series of protein cleavages. DNA damage or ceramide induce mitochondria-mediated 
apoptosis by releasing cytochrome c which binds to Afap-1 in cytosol and activates the 
caspase-9 cascade. 
Polyamine-mediated apoptosis is induced through the intrinsic apoptosis pathway 
due to mitochondrial damage (32, 105). Activation of PAO-mediated polyamine 
catabolism in response to excessive polyamine levels has been shown to be responsible 
for this apoptosis, since inhibition of PAO activity by MDL-72527 prevents cells from 
apoptosis (32). H2O2 generated during polyamine catabolism is the key molecule 
responsible for polyamine mediated apoptois as depletion of H2O2 by catalase prevents 
cells from death (32). H2O2 has been shown to cause DNA damage in this apoptosis 
(243). 
 
Polyamines Mediate AM Apoptosis during PCP 
 
As described previousely, one of the mechanisms which cause AM number decrease 
during PCP is the increased apoptosis rate. This apoptosis has been proven to be caused 
by elevated polyamine levels (105). The levels of spermidine, N1-acetylspermidine, and 
N1-acetylspermine were greatly increased by by 7-, 5-, and 7-fold in AM and 13-, 10-, 
and 10-fold in BALF, respectively in rats during PCP. These polyamines have been 
confirmed to cause macrophage apoptosis in a depletion-and-add back experiment. BALF 
obtained from Pneumocystis-infected animals has the ability induce normal AMs to 
undergo apoptosis. This ability is diminished when the polyamines in the BALF are 
depleted and regained when polyamines are added back. This apoptosis has also been 
found to be associated with the activations of caspase-3 and caspase-9, release of 
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cytochrome c from mitochondria, and induction of ROS productions. These results 
suggest that polyamine-mediated AM apoptosis during PCP is through the intrinsic 
pathway and is very likely caused by increased polyamine catabolism (105). 
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OBJECTIVE 
 
Rationale 
 
Pneumocystis infection usually occurs in individuals with critically low CD4+ T cell 
numbers. Decreased CD4+ T cell-mediated immunity leads to impaired innate and 
adaptive immune responses to allow Pneumocystis infection. 
AM is the major cell type responsible for innate responses in the lung. A significant 
body of evidence has demonstrated the crucial role of AMs in the defence of 
Pneumocystis infection (96, 103, 117). Unfortunately, the overall function of AM is 
defective during PCP. This is caused by at least two mechanisms: decreasd phagocytosis 
(96) and decreased AM number (102). Decreased AM phagocytic activity of 
Pneumocystis is at least partly caused by downregulation in the expressions of the 
transcription factor GATA-2 (206) and membrane receptor MR (96). Gene transfer of 
GATA-2 or MR enhances the ability of AMs to phagocytose Pneumocystis (51, 106, 249). 
Decreased AM number during PCP is caused by increased apoptosis (103). This 
apoptosis has been confirmed to be caused by greatly increased intracellular polyamine 
levels as described above (105). 
The purpose of this study is to determine the mechanism of polyamine induced 
apoptosis in AMs during PCP and to search for compounds which can inhibit this 
apoptosis. 
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Hypothesis 
 
This study is based on the hypothesis that the increase in intracellular polyamine 
levels in alveolar macrophages is due to both increased production and uptake of 
exogenous polyamines that are produced by Pneumocystis organisms and inflammatory 
cells. 
 
Specific Aims 
 
1. To investigate the mechanism that causes the increased polyamine levels in AMs 
during PCP. 
2. To determine the substance which induces AM apoptosis during PCP. 
3. To search for compounds which target polyamine-mediated apoptosis as a 
therapeutic approach against PCP. 
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MATERIALS AND METHODS 
 
Rat PCP Model 
 
Pneumocystis carinii infection in rats was established as described previously (12). 
Briefly, female Sprague-Dawley rats (Harlan, Indianapolis, IN) of 120-140 g were 
divided into three groups designated Normal, Dex, and Dex-Pc. Normal rats were 
immunocompetent and uninfected. Dex rats were treated continuously with 1.8 mg/liter 
dexamethasone in drinking water to reduce the number of CD4+ T lymphocytes, 
mimicking the immunosuppression status in AIDS patients. Dex-Pc rats were 
immunosuppressed with dexamethasone and transtracheally inoculated with 7.5 × 106 
trophic form of Pneumocystis one week after initiation of immunosuppression. To 
prevent other opportunistic infections, 10,000 units of penicillin (Butler, Dublin, OH) 
were given intramuscularly (i.m.) each week to each Dex and Dex-Pc rat. This antibiotic 
had no adverse effects on the growth of Pneumocystis organisms in infected rats. It took 
approximately eight weeks for Dex-Pc rats to develop severe Pneumocystis pneumonia 
after inoculation. When Dex-Pc rats were agonal, they were sacrificed for experiments. 
Age-matched Normal rats were used as controls, while age-matched Dex rats were used 
to control for effect of the steroid treatment. Giemsa staining of lung impression smears 
was performed to determine the existence of Pneumocystis and other microorganisms. 
Dex-Pc lungs were excluded if they contained other microorganisms. All animal studies 
were approved and supervised by the Indiana University Animal Care and Use 
Committee under Institutional Animal Care and Use Committee (IACUC) guidelines. 
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Isolation of AMs 
 
To perform bronchoalveolar lavage, rats were first anesthetized by i.m. injection of 
0.1 ml ketamine mixture (80 mg/ml ketamine hydrochloride, 0.38 mg/ml atropine, and 
1.76 mg/ml acepromazine) and then sacrificed. The thoracic cavity and trachea were 
exposed by dissection. BALF was obtained by instilling 5 ml of sterile phosphate 
buffered saline (PBS) into rat lungs via a 14-gauge angiocath (BD Biosciences, Bedford, 
MA) and then recovering the fluid. In experiments using BALF as supplement in cell 
cultures, Dulbecco's Modified Eagle's Medium (DMEM) instead of PBS was used for 
lavage. To isolate AMs, multiple lavages were performed until a total of 50 ml BALF was 
obtained. The cells in this 50-ml BALF were pelleted by centrifugation at 300 × g for 10 
min and then resuspended in 5 ml of DMEM. AMs were isolated by adherence on plastic 
tissue culture dishes at 37°C with 5% CO2 for 1 hr followed by washing with warm PBS 
three times to remove unattached cells. The purity of AMs was greater than 97% as 
determined by anti-RMA staining described previously (60, 63). 
 
Real-Time RT-PCR 
 
Total RNA was isolated using the TRIZOL reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instructions. Reverse transcription was done using the iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA) with a thermal condition of 25°C for 2 min, 
42°C for 30 min, and 85°C for 5 min. RNA (0.2 µg) from each sample was reverse 
transcribed to cDNA, and 2 µl of each cDNA product was used as the template for 
real-time PCR. Real-time PCR analyses for expression of rat ODC, SSAT, SRM, OAZ, 
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and AZI genes were performed using the Assays-on-Demand gene expression kits 
(Applied Biosystems, Foster City, CA); each of which contained two primers and a 
FAM-labeled probe. The mRNA levels of the ribosomal protein S8 (RPS8) gene was 
determined in an identical manner to serve as the internal control since its expression is 
not affected by immunosuppression or infection (247). The primers and probe used for 
the rat RPS8 real-time RT-PCR were described previously (247). Real-time PCR 
reactions were performed with TaqMan Universal PCR Master Mix (Applied Biosystems) 
on a Smartcycler (Cepheid, Sunnyvale, CA) using the following temperature cycling 
conditions: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 92°C for 15 sec and 60°C 
for 1 min. 
 
Western Blotting 
 
AMs adhered in one well of a 6-well plate (approximately 2 × 106 cells) were 
scraped in 100 μl cold (4°C) cell lysis buffer (150 mM NaCl, 1.0% Triton X-100, 1% 
deoxycholate, 5 mM EDTA, 10 mM Tris, pH 7.2) containing 1% protease inhibitor 
cocktail (Sigma #P8340). Protein samples for Western blot analysis were prepared by 
adding NuPAGE LDS Sample Buffer (Invitrogen) and NuPAGE Sample Reducing Agent 
(Invitrogen) to the cell lysates to a final concentration of 1 × of each reagent and then 
boiling for 5 min. Proteins in each sample were electrophoresed in a 10% polyacrylamide 
gel and then transferred onto a polyvinylidene difluoride (PVDF) membrane using the 
NuPAGE System (Invitrogen). Membranes were blocked by soaking in a buffer 
containing 3% bovine serum albumin (BSA), 0.9% NaCl, 100 mM Tris-HCl (pH 7.6) at 
25°C for 1 h and then reacted with the primary antibody anti-ODC (Lab Vision, Fremont, 
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CA), anti-SSAT (Novus Biologicals, Littleton, CO), anti-OAZ (87, 88), anti-AZI (147), 
anti-cleaved or activated caspase 3 (Cell Signaling, Danvers, MA), or 
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Research Diagnostics, 
Flanders, NJ) in blocking buffer for 2 hr. After washing with TBST (100 mM Tris-HCl, 
0.9% NaCl, 0.1% Tween 20, pH 7.6) six times, the blots were reacted with a secondary 
antibody anti-mouse IgG or anti-rabbit IgG conjugated with horseradish peroxidase (HRP) 
for 1 hr at 25°C followed again by six washes with TBST. The reaction signals on the 
blots were developed by chemiluminescence with the ECL Plus reagent kit (Amersham 
Biosciences, Piscataway, NJ) and revealed by exposing the blots to an X-ray film. 
Densitometry analysis of results on X-ray films was performed by using the ImageJ 
software (http://rsb.info.nih.gov/ij/). 
 
Fluorescence Labeling of Spermidine 
 
Labeling of spermidine with fluorescein was performed as previously described (1) 
with modifications. Due to poor stability in solution, the fluorophore 5-(and-6)-carboxyl 
fluorescein succinimidyl ester (FAM) (Invitrogen) was freshly prepared in 
dimethylsulfoxide (DMSO) at a final concentration of 100 mM immediately before use. 
Spermidine was dissolved in 200 mM NaHCO3 (pH 8.3) to a final concentration of 2 mM. 
The labeling reaction was performed by mixing 20 μl of FAM with 1 ml of spermidine in 
a 2-ml eppendorf tube. The tube was fastened on a vortexer and shaken for 1 hr at room 
temperature. The labeled products were separated by electrophoresis in a 1% agarose gel 
in 40 mM 2-(N-morpholino) ethanesulfonic acid monohydrate (MEM) buffer (pH 6.0) at 
100 V for 1 hr and then visualized by UV transillumination. The FAM-labeled spermidine 
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(FAM-SPD) moved toward the anode and exhibited an extra band as compared to the 
sample containing FAM only. The portion of the gel containing FAM-SPD or FAM was 
excised, chopped to small cubes, and placed at -80°C until completely frozen. FAM-SPD 
was recovered by centrifugation at 10,000 × g for 2 h at 4°C. Additional centrifugations 
were performed if the gel was not completely thawed. The concentration of recovered 
FAM-SPD was determined by spectrophotometry at 494 nm using known concentrations 
of FAM as standards. The yield of FAM-SPD was ≥ 30 μM. Purified FAM-SPD was 
stored in small aliquots at -80°C until use. 
 
Polyamine Uptake Assay 
 
For in vivo polyamine uptake assay, each Normal, Dex, and Dex-Pc rat was 
anesthetized with 100 μl ketamine cocktail i.m. and then transtracheally instilled with 200 
μl of 5 μM FAM-SPD or FAM. AMs were then isolated as described above 1 hr after the 
FAM-SPD or FAM instillation. The cells were mounted on slides in a mounting medium 
containing 4',6-diamidino-2-phenylindole (DAPI) to stain the nuclei. The macrophages 
which took up FAM-SPD were detected and enumerated by fluorescence microscopy. To 
examine polyamine uptake in Pneumocystis-infected lungs, frozen lung sections of 
FAM-SPD instilled rats were used. The lungs were first lavaged with 2 ml of PBS 3 times 
to remove free FAM-SPD or FAM, then instilled with 2 ml of the OCT compound 
(Sakura, Tokyo, Japan) via a 14-gauge angiocatheter. Each lung was then placed in a base 
mold filled with OCT and frozen at -80°C. The frozen lungs were sectioned with a 
cryostat microtome, and the sections were stored at -80°C until use. Frozen lung sections 
were air dried for 15 sec and fixed in acetone for 2 min before staining. After an 
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incubation in 5% BSA for 1 hr, the lung sections were reacted with Phycoerythrin 
(PE)-conjugated anti-CD68 antibody in 5% BSA in PBS for 1 hr to stain macrophages 
followed by three washes with PBS. The nuclei were counterstained with DAPI, and the 
stained slides were examined by fluorescence microscopy. The polyamine uptake assay 
was also performed in isolated AMs after AZI siRNA knockdown. This ex vivo 
polyamine uptake assay was performed by incubating AMs with 2.5 μM FAM-SPD in 
serum-free DMEM for 1 hr followed by fluorescence microscopy described above. 
 
Immunohistochemical (IHC) Staining 
 
Rat lungs were fixed in 4% paraformaldehyde overnight and then embedded in 
paraffin. Tissue sections on slides were processed for IHC staining by boiling the 
deparaffinized sections in the High pH Target Retrieval Solution (DAKO, Carpinteria, 
CA) for 20 min to expose hidden antigens. After three PBS washes, sections were 
immersed in 3% hydrogen peroxide for 5 min to deplete the endogenous peroxidase 
activity. Immunostaining was performed using the UltraVision LP System with HRP 
Polymer (Lab Vision, Fremont, CA). Briefly, sections were incubated in 1% BSA in PBS 
for 30 min followed by antibody staining at room temperature for 2 hr. Monoclonal 
antibodies against rat ODC (MP16-2), CD68 (KP1), CD79a (HM47/A9), and CD3ζ 
(6B10) were purchased from Lab Vision, while polyclonal anti-spermidine antibody was 
acquired from Abcam (Cambridge, MA). The anti-spermidine antibody also cross reacts 
with spermine according to the manufacturer. Primary Antibody Enhancer and HRP 
polymer were used according to manufacturer’s instructions. Final chromogenic reaction 
was performed with the metal enhanced DAB substrate (Pierce, Rockford, IL). 
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Flow Cytometry 
 
Isolation of single cells from Pneumocystis-infected rat lungs was performed as 
described previously (234). Each anesthetized rat was perfused with 30 ml cold 
Dulbecco’s PBS (D-PBS) via right ventricle. A total of 5 ml Dispase II (neutral protease) 
(5 mg/ml) (Sigma) was transtracheally injected into the lungs, and the trachea was ligated 
with suture silk to avoid leakage. Lungs containing Dispase II were incubated in D-PBS 
for 45 min at 37°C. The lungs were then cut into small pieces and incubated in 5 ml 
D-PBS containing 1 mg/ml of collagenase/Dispase (Roche, Indianapolis, IN) and 0.08 
mg/ml of DNase I Type II (Sigma) for 10 min at 37°C with shaking. Digested lungs were 
forced through an 18 g needle ten times and then mixed with 2 ml of fetal bovine serum. 
Single cells were isolated by filtering through a 70-μm nylon mesh and collected by 
centrifugation at 300 × g for 10 min. The pelleted cells were treated with 2 ml RBC lysis 
buffer (Sigma) to remove red blood cells, followed by washing with 10 ml PBS two times 
and then enumerated with a hematocytometer. Approximately one million cells were used 
for each flow cytometric analysis. FITC-conjugated anti-ODC antibody was made by 
using the FITC Microscale Protein Labeling Kit (AnaSpec, San Jose, CA). PE-conjugated 
antibodies against CD4, CD8, and CD45RA were purchased from Cedarlane (Burlington, 
NC). The PE-conjugated anti-CD68 antibody was acquired from AbD Serotec (Raleigh, 
NC). FITC- and PE-conjugated mouse IgG1 antibodies were used as isotype controls. 
The stained cells were analyzed with a FACScan flow cytometer (BD Biosciences, San 
Jose, CA), and the data were interpreted by the BD CellQuest Software. 
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AZI Knockdown with siRNA 
 
The rat AZI siRNA duplex and scrambled siRNA were synthesized by Integrated 
DNA Technologies (Coralville, IA). The sequence of the AZI siRNA was 
AAGAUCGUGAAGAAGCACAGU which has been shown to be effective against AZI 
expression (61). To perform siRNA knockdown, approximately 2 × 106 AMs were placed 
in a well of a 6-well plate containing 2 ml serum-free DMEM. The cells were transfected 
with the siRNAs by adding 2 μl of 1 μg/μl of siRNA molecules and 5 μl of 
TransMessenger (Qiagen, Valencia, CA) to the well. After 6 hr of incubation at 37°C with 
5% CO2, the culture medium was supplemented with a final concentration of 10% FBS, 
1% antibiotic mixture (Sigma #P4333), and 2 ml of DMEM-based BALF to mimic the 
original lung environment. The cells were harvested after three days of incubation for 
real-time RT-PCR, Western blotting, and polyamine uptake assays described above. 
 
Apoptosis Assay 
 
Macrophage apoptosis was determined using the DeadEnd Fluorimetric Fluorescent 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) System 
(Promega, Madison, WI). Briefly, deparaffinized and rehydrated rat lung sections on 
slides were digested with 20 μg/ml of proteinase K at room temperature for 10 min. After 
washing with PBS, the sections were incubated with terminal deoxynucleotidyl 
transferase and fluorescein-12-dUTP at 37°C for 1 hr to label DNA fragments at their 3’ 
ends. Unincorporated fluorescein-12-dUTPs were removed by washing the slides two 
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times with 2 × saline sodium citrate buffer. Slides were mounted with ProLong Gold 
antifade reagent containing DAPI (Invitrogen) which stains DNA. 
 
Cytosolic Cytochrome c Assay 
 
Determination of cytosolic cytochrome c levels was performed as described 
previously (105). Briefly, 2 × 106 AMs were lysed, and the protein concentrations in the 
cell lysate were determined by the Bradford protein assay method (Bio-Rad). A total of 5 
μg protein in 100 μl blocking buffer was used to determine the levels of cytochrome c by 
the FunctionELISA cytochrome c assay kit (Active Motif, Carlsbad, CA). This kit uses 
the Sandwich ELISA technique with the first antibody to capture and the 
biotin-conjugated second antibody coupled with HRP-conjugated streptavidin to quantify 
cytochrome c. 
 
PAO and SMO Activity Assay 
 
PAO activity was assayed by the method of Suzuki et al. (202), which measures the 
levels of H2O2 formed. H2O2 converts homovanillic acid to a fluorescent compound in 
the presence of HRP. AMs (approximately 2 × 106 cells) from each rat were suspended in 
1 ml of 83 mM sodium borate (pH 9.0) and broken up by passing through a 1 ml syringe 
with 25 gauge needle 20 times. Five hundred microliters of cell lysate was preincubated 
with 5U of HRP for 20 min at 37°C to remove endogenous substrates of hydrogen 
peroxide-producing enzymes. One hundred micrograms of homovanillic acid and 
N1-acetylspermine (final concentration 250 µM) were then added, followed by an 
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incubation at 37°C for 30 min. The PAO reaction was stopped by adding 1 ml of 0.1 M 
NaOH solution. The intensity of fluorescence generated in the reaction was measured by 
fluorometry with an excitation wavelength of 323 nm and emission wavelength of 426 
nm. Protein concentration was determined with Bradford protein assay dye (Bio-Rad), 
and PAO activity was shown in the amount H2O2 produced per min per mg of protein. 
SMO activity was measured by the same method except that the substrate was replaced 
by spermine. 
 
Cytotoxicity of Polyamine Transport Ligands 
 
The anthracene-polyamine conjugates Ant-(butanediamine) (232), Ant-(4,4) (231), 
Ant-(4,4,4) (230), 44-Ant-44 (86), and 44-Bn-44 (86) were previously synthesized and 
characterized in terms of their structures, Ki values versus radiolabeled spermidine, and 
polyamine transport targeting abilities in CHO cell lines (Fig. 26). Toxicity of polyamine 
transport inhibitors to AMs was determined by Trypan blue exclusion assay. AMs were 
isolated as described previously (115). A total of one million AMs from normal rats were 
placed in one well of a 12-well plate and incubated with a certain compound at various 
concentrations. After a 3 hr incubation, cells were stained with 0.4% Trypan Blue 
solution (Invitrogen, Carlsbad, CA), and the numbers of viable cells (unstained cells) 
were enumerated. 
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Treatment of PCP rats with Polyamine Transport Ligands 
 
Dex-Pc rats were given 50 μl of 1 mM 44-Ant-44 or 44-Bn-44 intranasally every 
two days starting at the 28th day after infection. All rats were sacrificed after 84 days of 
infection. 
 
Pulmonary Pathology 
 
Rats were anesthetized by i.m. injection of 100 μl ketamine mixture (80 mg/ml 
ketamine hydrochloride, 0.38 mg/ml atropine, and 1.76 mg/ml acepromazine) and then 
sacrificed. The thoracic cavity was exposed by dissection. The whole lung was excised 
and then fixed with 4% paraformaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 mM KH2PO4, pH 7.4) overnight. Sections of paraffin-embedded lung 
were stained with hematoxylin & eosin (H&E) and then examined by light microscopy. 
The degree of pulmonary inflammation was graded on a scale of 0 to 5 as previously 
described (183). Briefly, grade 0 had no lesions; grade 1 had minimal lymphocytic 
inflammation restricted to perivascular and peribronchiolar regions; grade 2 had moderate 
perivascular and peribronchiolar inflammation with a slight increase in the numbers of 
AMs, lymphocytes, and eosinophils; grade 3 had profound perivascular and 
peribronchiolar inflammation with moderately increased numbers of alveolar 
macrophages, lymphocytes, eosinophils, and multinucleated giant cells; grade 4 had 
severe perivascular and peribronchiolar inflammation with markedly increased numbers 
of alveolar macrophages, eosinophils, lymphocytes and multinucleated giant cells; grade 
5 had severe perivascular and peribronchiolar inflammation with effacement of alveolar 
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parenchyma and small airways by sheets of inflammatory cells. This grading was 
performed by a pathologist on blinded samples. 
 
Pneumocystis Burden 
 
The numbers of Pneumocystis organisms in lung sections were enumerated after 
being stained with GMS silver (Sigma). Briefly, deparaffinized and rehydrated lung tissue 
sections were placed in 1% periodic acid solution for 5 min and then washed with water. 
Silver staining was performed by incubating the lung sections with freshly prepared 
working silver solution (110 mg silver methenamine in 0.4% sodium borax) at 62°C for 
20 min. The sections were then reacted with 0.2% gold chloride for 30 sec. Excess silver 
was removed by incubating the slides with 2% sodium thiosulfate for 2 min. Sections 
were counterstained with 0.2% Light Green and then examined by light microscopy. 
Organism burden was graded on a scale of 0 to 4 as previously described (183). Briefly, 
grade 0 indicated no cysts; grade 1 had scattered cysts; grade 2 had cysts in most alveoli 
surrounding tertiary bronchioles; grade 3 had cysts throughout alveoli in many regions; 
grade 4 had cysts and foamy exudate throughout alveoli in most regions. This grading 
was performed by a pathologist on blinded samples. 
 
Statistical Analysis 
 
Data were presented as means ± SD with indicated number of experiments. 
Two-tailed student's t-test was used for statistical analysis, and the difference between the 
two groups analyzed was considered statistically significant if the p value was < 0.05. 
 54
RESULTS 
 
Polyamine Synthesis in AMs during PCP 
 
To examine whether the increased polyamine levels in AMs during PCP are due to 
increased polyamine synthesis, the expression levels of ODC, SSAT, and SRM were 
determined by real-time RT-PCR and Western blotting. The results showed that the 
mRNA levels of ODC, SSAT, and SRM in AMs from immunosuppressed (Dex) rats were 
0.93, 1.54, and 1.21 fold, respectively of those of Normal rats (Fig. 4). Since these 
differences were not statistically significant, the results indicated that long-term treatment 
of rats with dexamethasone did not significantly affect polyamine synthesis mediated by 
ODC, SSAT, or SRM. In AMs from Dex-Pc rats, ODC, SSAT, and SRM mRNA levels 
were 1.01, 0.94, and 1.01 fold that of Dex rats (data not shown), indicating that 
Pneumocystis infection also did not significantly affect the transcription of these genes. 
Western blotting analysis revealed that the level ODC protein in AMs was not changed by 
immunosuppression but was increased approximately 8-fold during Pneumocystis 
infection (Fig. 5). In contrast, the SSAT protein level was not altered during 
Pneumocystis infection (Fig. 5). The protein level of SRM was not determined because an 
anti-rat SRM antibody was not commercially available. The change in ODC protein but 
not mRNA levels indicated that ODC expression was regulated by a posttranscriptional 
mechanism in AMs during PCP. 
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Polyamine Uptake by AMs during PCP 
 
Elevated intracellular polyamine levels could also be due to increased polyamine 
uptake; therefore, polyamine uptake assays were performed. Purified FAM-labeled 
spermidine (FAM-SPD) (Fig. 6) was transtracheally instilled into the lungs of Normal, 
Dex, and Dex-Pc rats. Rats were sacrificed and lavaged to obtain AMs one hour after the 
transtracheal instillation. Fluorescence microscopy showed that less than 0.1% of AMs 
from Normal and Dex rats but greater than 2% of those from Dex-Pc rats contained 
FAM-SPD (Fig. 7), suggesting that the number of AMs that can take up exogenous 
polyamines was increased by approximately 20 fold during PCP (Fig. 7). To confirm that 
these cells took up FAM-SPD not FAM non-specifically, a separate group of Dex-Pc rats 
were transtracheally instilled with FAM. This experiment revealed that less than 0.1% 
AMs in this group of rats internalized FAM (Fig. 7), confirming the specificity of 
polyamine uptake. To identify the cells which took up polyamines, frozen lung sections 
from FAM-SPD instilled Dex-Pc rats were stained for the macrophage marker CD68, and 
all the cells that contained FAM-SPD were positive for CD68 (Fig. 8), indicating that 
they were macrophages. 
  
ODC Expression in Rat Lungs during PCP 
 
To determine the sources of polyamines in the lung during PCP, IHC staining for 
ODC was performed on lung sections from Normal, Dex, and Dex-Pc rats. H&E and 
ODC staining revealed no differences in the microscopic features of the lungs from 
Normal and Dex rats, indicating that immunosuppression of rats with dexamethasone had 
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no effect on ODC expression. However, ODC expression in the lung was greatly affected 
by Pneumocystis infection. The ODC protein was not detectable in most pulmonary cells, 
but was highly expressed in the mononuclear cells located around blood vessels and 
bronchioles (Fig. 9), suggesting that these inflammatory cells were sources of polyamines 
during PCP. Interestingly, the intracellular location of ODC was changed during PCP. In 
uninfected rats, ODC was found distributed evenly in the cytoplasm of inflammatory 
cells from uninfected rats, but was located in pericytoplasmic areas in those from infected 
rats (Fig. 9). To identify these cells, serial lung sections from Dex-Pc rats were stained 
with cell-specific markers CD68 (monocyte), CD79a (B lymphocyte), and CD3ζ (T 
lymphocyte). Results showed that these ODC-positive cells may be monocytes and B or 
T lymphocytes (Fig. 10). Polyamine production determined by anti-spermidine staining 
also showed that the cells in this area contain high levels of polyamines (Fig. 10). 
 
Flow cytometry analysis of ODC-positive cells in Pneumocystis-infected lungs 
 
To quantify and further identify ODC-positive cells, total lung cells isolated from 
Dex-Pc rats were analyzed by flow cytometry. Anti-ODC antibody was labeled with 
FITC, and antibodies against CD4, CD8, CD45RA, and CD68 were labeled with PE. In 
this assay, 24.44% of total lung cells from Dex-Pc rats were ODC-positive (Table 1). 
Dual staining of the cells with ODC and CD4, CD8, CD45RA, or CD68 antibodies 
revealed that 1.83% of the cells were ODC+CD4+, 8.27% were ODC+CD8+, 9.79% 
were ODC+CD45RA+ (B lymphocytes), and 7.80% were ODC+CD68+ 
(monocytes/macrophages). 
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OAZ and AZI Expression in AMs during PCP 
 
Since OAZ and AZI have been shown to regulate both polyamine production and 
transport (59, 96), their expressions in AMs from Normal, Dex, and Dex-Pc rats were 
determined. Real-time RT-PCR results revealed that the mRNA expression levels of OAZ 
in AMs from Dex and Dex-Pc rats were 0.93 and 0.96 fold, respectively of those of 
Normal rats (Fig. 11); these differences were not statistically significant. Western blotting 
results also showed that OAZ protein levels in AMs were not affected by 
immunosuppression or Pneumocystis infection (Fig. 12). In contrast, AZI mRNA levels in 
AMs from Dex-Pc rats were 3.16 fold higher than those from Dex rats (Fig. 11), and AZI 
protein levels in AMs were increased by 6 fold during PCP as determined by Western 
blotting (Fig. 12). 
 
Polyamine Synthesis and Uptake after AZI Knockdown 
 
To correlate AZI overexpression with AM apoptosis during PCP, AMs isolated from 
Dex-Pc rats were analyzed for AZI expression, polyamine synthesis, polyamine uptake, 
and apoptosis after AZI siRNA knockdown. Results from real-time PCR showed that AZI 
siRNA successfully decreased AZI mRNA levels by approximately 70% in AMs from 
Dex-Pc rats (Fig. 13). This AZI knockdown was also found to cause a 60% decrease in 
ODC protein level in these AMs (Fig. 14). In the ex vivo spermidine uptake assay, a 50% 
reduction in the number of cells taking up polyamines was observed in the group of cells 
transfected with AZI siRNA as compared to control transfectants (Fig. 15). 
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Macrophage Apoptosis after AZI Knockdown 
 
BALF from Pneumocystis-infected rats have been shown to induce macrophages to 
undergo apoptosis due to elevated levels of polyamines (105). To determine whether AZI 
plays a role in this BALF-induced apoptosis, 2 × 106 normal rat AMs were transfected 
with AZI siRNA and then incubated with BALF from Dex-Pc rats 6 hr after siRNA 
transfection. Three days after the transfection and BALF treatment, cells were analyzed 
for apoptosis by three different methods. Results from TUNEL assay showed that the 
number of apoptotic cells was decreased by 53% (Fig. 16). The levels of cytosolic 
cyotochrome c showed a 58% reduction (Fig. 17), and those of activated caspase-3 
determined by Western blotting were decreased by 75% in macrophages transfected with 
AZI siRNA as compared to controls that were transfected with scrambled siRNA (Fig. 
18). 
 
Substances That Induce AZI Overexpression 
 
Since AZI was found overexpressed in AMs from Dex-Pc rats, experiments were 
performed to determine whether certain substances capable of inducing the expression of 
AZI are present in BALF from Dex-Pc rats. AMs from normal rats were first treated with 
the Dex-Pc BALF and then measured for AZI mRNA by RT-PCR. This treatment resulted 
in a 1.5 fold increase in AZI mRNA levels in AMs compared to the same cells treated 
with Dex BALF (Fig. 19), suggesting that AZI expression in AMs can be induced by a 
certain substance in Pneumocystis-infected lungs. To identify this substance, AMs from 
normal rats were treated with Pneumocystis organisms and the cytokine TNF-α which is 
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present in high levels in Pneumocystis-infected lungs. Results showed that Pneumocystis 
organisms but not TNF-α increased AZI mRNA levels in a dose-dependent manner (Fig. 
20). The same result was observed when normal rat AMs were treated with zymosan A 
(Fig. 20). These results suggest that a component of the Pneumocystis cell wall is 
responsible for the increase in AZI expression during PCP. 
 
Polyamine Catabolism and AM Apoptosis 
 
To investigate whether polyamine catabolism plays a role in AM apoptosis during 
PCP, the expression and activity levels of PAO and SMO in AMs from 
Pneumocystis-infected rats were determined. Results of real-time RT-PCR showed that 
PAO mRNA levels in AMs from Dex-Pc rats were 2.82 fold that of those from Dex rats, 
but SMO mRNA levels were not significantly changed (Fig. 21). PAO protein levels were 
found increased approximately 4 fold in AMs during PCP (Fig. 22), and PAO activity in 
AMs from Pneumocystis-infected rats showed a 2.24 fold increase as compared to the 
Dex control (Fig. 23). These results suggest that polyamine oxidation plays a role in AMs 
apoptosis in Pneumocystis-infected lungs. 
 
Acetylated Polyamines Induce PAO expression 
 
As described previously, the activity and levels of both mRNA and protein of PAO 
are increased in AM during PCP (115). To determine whether this increase is caused by 
the markedly increased levels of N1-acetylspermidine and N1-acetylspermine which are 
the substrates of PAO (105), mouse macrophage cell line RAW 264.7 cells were 
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incubated with varying concentrations (20 - 160 μM) of spermidine, spermine, 
N1-acetylspermidine, and N1-acetylspermine for 24 hrs and then assessed for PAO 
mRNA and protein levels. Results from real-time RT-PCR revealed that 
N1-acetylspermidine and N1-acetylspermine induced PAO mRNA expression in a 
dose-dependent manner and caused a 4.84 ± 0.62 and 22.12 ± 0.75 fold increase, 
respectively (Fig. 24), in PAO mRNA levels at a concentration of 160 μM. PAO mRNA 
levels were also increased by spermidine and spermine, although at much lower levels. 
The highest level of PAO mRNA induced by spermidine was 1.44 ± 0.17 fold at 160 μM, 
and that induced by spermine was 1.83 ± 0.3 fold at 80 μM. With Western blotting, PAO 
protein levels in AMs were also found to be elevated by treatment of the cells with 
spermidine, spermine, N1-acetylspermidine, and N1-acetylspermine at 160, 80, 40, and 
40 μM, respectively (Fig. 25). These results confirm the hypothesis that PAO expression 
is induced by its substrates N1-acetylspermidine and N1-acetylspermine. Since PAO also 
utilizes spermine as its substrate and converts it to spermidine (188), it is not surprising to 
see a moderate PAO induction by spermine. Spermidine is not the natural substrate of 
PAO, but it can be converted to N1-acetylspermidine by SSAT (235). This may be why 
PAO expression was also induced by spermidine. 
 
Cytotoxicity of Polyamine Transport Inhibitors 
 
Polyamine uptake is increased in AMs during PCP and this increase is very likely to 
contribute to disease progress during PCP. To investigate whether inhibiton of polyamine 
transport can be a therapeutic target against PCP, five potential polyamine transport 
inhibitors, compounds Ant-(butanediamine), Ant-(4,4), Ant-(4,4,4), 44-Ant-44, and 
 61
44-Bn-44 (Fig. 26), were tested in vivo. Since these compounds had not been used in vivo, 
their toxicity to AMs from normal rats was first determined. Trypan blue exclusion assays 
showed that less than 16% of the cells were viable after 3 h incubation with 0.4 mM of 
Ant-(butanediamine) or Ant-(4,4), indicating that these two compounds were toxic to 
AMs. Compound Ant-(4,4,4) was less toxic as 88% of the cells remained viable after 3 hr 
of treatment with the lowest concentration (0.4 mM) and 42% with the highest 
concentration (2 mM). There was no significant change in viability after the cells were 
treated for 3 h with compound 44-Ant-44 or 44-Bn-44 at concentrations up to 2 mM, 
indicating that these two compounds were not toxic to AMs (Fig. 27). 
 
Effects of 44-Ant-44 and 44-Bn-44 on Survival of Rats with PCP 
 
Since compounds 44-Ant-44 and 44-Bn-44 showed no cytotoxicity in vitro, their 
therapeutic effects on PCP were examined. Eight rats that had been infected with 
Pneumocystis carinii (Dex-Pc rats) for 28 days were treated intranasally with 50 μl of 1 
mM of 44-Ant-44 or 44-Bn-44 every two days. Immunosuppressed and uninfected (Dex 
rats, n=4) and untreated Dex-Pc (n=9) rats were included in this study as controls. All 
Dex rats survived the entire 84 days of the study, while untreated Dex-Pc rats died at 
different times. On average, 44-Ant-44-treated Dex-Pc rats lived eight days longer and 
44-Bn-44 treated Dex-Pc rats lived two days longer than untreated Dex-Pc rats (Fig. 28). 
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Effects of 44-Ant-44 and 44-Bn-44 on Lung Pathology and Organism Burden 
 
Light microscopy of H&E stained lung sections from Dex-Pc rats treated for 21 days 
with the compounds revealed that 44-Ant-44 treatment increased open alveolar space, 
reduced alveolar septa thickness, reduced inflammation, and decreased foamy exudates in 
alveoli as compared to those from untreated Dex-Pc rats. Lung sections from 44-Bn-44 
treated Dex-Pc rats showed a slight decrease in inflammatory cell infiltration but no 
apparent changes in alveolar structure and foamy exudates. The overall inflammatory 
scores for untreated, 44-Ant-44-treated, and 44-Bn-44-treated Dex-Pc rats were 
determined to be 3.63 ± 0.48, 2.3 ± 0.27, and 3.17 ± 0.29, respectively on a scale of 0 to 5 
(Fig. 29). These results indicated that 44-Ant-44 substantially reduced the pulmonary 
damage caused by Pneumocystis infection (p = 0.001), but 44-Bn-44 had little effect (p = 
0.206). The overall organism burden on a scale of 0 to 4 of 44-Ant-44-treated Dex-pc rats 
was determined to be 0.8 ± 0.27, whereas those of untreated and 44-Bn-44 treated 
Dex-Pc rats were 3 ± 0 and 2.17 ± 0.29, respectively (Fig. 30). These results indicated 
that both 44-Ant-44 (p = 0.000001) and 44-Bn-44 (p = 0.002) decreased the organism 
burden in Pneumocystis-infected lungs, but 44-Ant-44 worked much better than 
44-Bn-44. 
 
Effects of 44-Ant-44 and 44-Bn-44 on Apoptosis of AM 
 
Results of TUNEL assays on lung sections from untreated, 44-Ant-44-treated, and 
44-Bn-44-treated Dex-Pc rats revealed that 21 days of treatment with 44-Ant-44 reduced 
 63
the number of apoptotic alveolar macrophages by 80% in the lungs (Fig. 31). In contrast, 
44-Bn-44 did not significantly reduce the apoptosis rate of AMs. 
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Table 1. Flow cytometry analysis of lung cells from Pneumocystis-infected rats. 
  FITC(-)PE(-) FITC(-)PE(+) FITC(+)PE(-) FITC(+)PE(+)
Isotype Control 95.75 ± 0.81 0.04 ± 0.07 2.54 ± 0.10 1.66 ± 0.84 
ODC-FITC 73.95 ± 5.43 0.00 ± 0.00 24.44 ± 6.78 1.61 ± 1.34 
ODC-FITC+CD4-PE 77.04 ± 4.37 0.07 ± 0.06 21.06 ± 5.40 1.83 ± 1.09 
ODC-FITC+CD8-PE 82.07 ± 2.59 0.02 ± 0.01 9.63 ± 1.60 *8.27 ± 0.99 
ODC-FITC+CD45RA-PE 82.73 ± 1.12 0.77 ± 0.58 6.71 ± 1.37 *9.79 ± 1.91 
ODC-FITC+CD68-PE 76.73 ± 3.19 0.00 ± 0.01 15.20 ± 8.01 *7.80 ± 4.42 
Results represent means ± SD from 4 experiments. 
* p < 0.05 compared to the FITC(+)PE(+) quadrant of the ODC-FITC group. 
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Polyamine Structures 
 
 
 
 
 
 
 
Fig. 1. Polyamine structures. 
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Polyamine Metabolism Pathway 
 
 
 
 
 
 
 
Fig. 2. Polyamine metabolism pathway. ODC, ornithine decarboxylase; OAZ, ODC 
antizyme; AZI, ODC antizyme inhibitor; PAO, polyamine oxidase; SMO, spermine 
oxidase, SSAT, spermidine/spermine N1-acetyltransferase; SRM, spermidine synthase; 
SMS, spermine synthase; SAMDC, S-adenosylmethionine decarboxylase. 
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AM Apoptosis during PCP 
 
 
 
 
 
 
 
Fig. 3. AM apoptosis during PCP. Lung sections from Normal, Dex, and Dex-Pc rats 
were analyzed by TUNEL assay which stains the apoptotic cell nuclei. TUNEL(+) cells 
were identified as AMs by their morphology and location. 
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mRNA Expressions of Polyamine Synthesis Enzymes in AMs 
 
 
 
 
 
 
 
Fig. 4. mRNA Expressions of Polyamine Synthesis Enzymes in AMs. mRNA levels of 
ODC, SSAT, and SRM in AMs were determined by real-time RT-PCR. Results represent 
mean ± S.D. from four experiments. No significant changes were found during PCP. 
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Protein Expressions of Polyamine Synthesis Enzymes in AMs 
 
 
 
 
 
 
 
Fig. 5. Protein expressions of polyamine synthesis enzymes in AMs. Protein levels of 
ODC and SSAT in AMs were analyzed by Western blotting. Results shown are 
representative of three independent experiments. 
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Purity of FAM-Labeled Spermidine 
 
 
 
 
 
 
 
Fig. 6. Purity of FAM-labeled spermidine. A totoal of 10 μl of 40 μM FAM and 
FAM-labeled spermidine (FAM-SPD) before and after purification by gel elution were 
electrophoresed in 1% agarose gel in 40 mM MES buffer and visualized by UV 
transillumination. FAM moved toward cathode, whereas FAM-SPD moved toward anode. 
Arrow indicates the position of loading wells. 
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Polyamine Uptake Assay 
 
 
 
 
Fig. 7. Polyamine uptake assay. (A) 200 μl of 5 μM FAM-SPD or FAM was 
transtracheally instilled into Normal, Dex, and Dex-Pc rats. AMs were isolated one hour 
after the instillation and examined by fluorescence microscopy. Arrows indicate the cells 
with internalized FAM-SPD. (B) A total of 1000 randomly selected cells of each sample 
shown in Panel A were counted, and the percentages of cells with internalized FAM or 
FAM-SPD were determined and diagrammed. Results represent mean ± S.D. from four 
experiments. Asterisk (*) indicates p < 0.05 as compared to Dex control. 
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Polyamine Uptake is Increased in AMs 
 
 
 
 
 
 
 
Fig. 8. Polyamine uptake is increased in AMs. Dex-Pc rats were transtracheally instilled 
with FAM-SPD. One hour after the instillation, rats were sacrificed, and frozen lung 
sections were made then stained for the macrophage marker CD68. Merged images 
showed that the cells that took up FAM-SPD were exclusively alveolar macrophages 
since every cell that took up polyamine was CD68 positive, and no CD68-negative cells 
took up polyamines. 
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ODC Expression in the Lung 
 
 
 
 
 
 
 
 
Fig. 9. ODC expression in the lung. H&E staining (top) and IHC staining for ODC were 
performed on lung sections form Normal, Dex, and Dex-Pc rats. Cells reacted with 
anti-ODC antibody were examined at the magnifications of 200 × (middle) and 1000 × 
(bottom). Open and solid arrows indicate the cells with homogenous and pericytoplasmic 
ODC expression patterns, respectively. Results shown are representative of three sets of 
animals. 
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Colocalization of ODC(+) and Inflammatory Cells 
 
 
 
 
 
 
 
Fig. 10. Colocalization of ODC(+) and inflammatory cells. IHC staining for CD68 
(monocyte), CD79a (B cell), CD3ζ (T cell), ODC, and spermidine was performed on 
serial sections from Dex-Pc lungs. The control was processed in an identical manner 
except that no primary antibody was used. Magnification = 200 ×. 
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OAZ and AZI mRNA Expressions in AMs 
 
 
 
 
 
 
 
Fig. 11. OAZ and AZI mRNA expressions in AMs. mRNA levels of OAZ and AZI in 
AMs from Normal, Dex, and Dex-Pc rats were determined by real time RT-PCR. Results 
represent means ± SD from 5 experiments. Asterisk (*) indicates p < 0.05 as compared to 
Dex control. 
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OAZ and AZI Protein Expressions in AMs 
 
 
 
 
 
 
 
Fig. 12. OAZ and AZI protein expressions in AMs. Protein levels of OAZ and AZI in 
AMs from Normal, Dex, and Dex-Pc rats were determined by Western blotting (n = 3). 
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siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 13. siRNA knockdown of AZI. Real time RT-PCR analysis of AZI mRNA levels 
after siRNA knockdown. AMs from Dex and Dex-Pc rats were transfected with AZI 
siRNA or scrambled siRNA and then measured for AZI mRNA levels. Results represent 
means ± SD from 4 experiments. Asterisk (*) indicates p < 0.05 as compared to 
scrambled control unless illustrated elsewhere. 
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Polyamine Synthesis after siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 14. Polyamine synthesis after siRNA knockdown of AZI. The ODC protein level in 
AMs from Dex-Pc rats was determined by Western blotting after transfection with AZI 
siRNA or scrambled siRNA. 
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Polyamine Uptake after siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 15. Polyamine uptake after siRNA knockdown of AZI. AMs from Dex-Pc rats were 
assayed for FAM-SPD uptake after transfection with AZI siRNA or scrambled siRNA. A 
total of 1000 cells of each sample were counted, and the percentages of cells with 
internalized FAM-SPD were determined and diagrammed. Results represent means ± SD 
from 4 experiments. Asterisk (*) indicates p < 0.05 as compared to scrambled control. 
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Macrophage Apoptosis after siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 16. Macrophage apoptosis after siRNA knockdown of AZI. (A) Normal rat AMs 
were transfected with AZI siRNA or scrambled siRNA and then treated with BALF from 
Dex-Pc rats. Three days after transfection, TUNEL assay was performed, and cells were 
examined by fluorescence microscopy. (B) A total of 1000 randomly selected cells of 
each sample shown in Panel A were counted, and the percentages of apoptotic cells were 
diagrammed. Results represent mean ± S.D. from three experiments. Asterisk (*) 
indicates p < 0.05 as compared to scrambled control. 
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Cytochrome c Release after siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 17. Cytochrome c release after siRNA knockdown of AZI. Normal rat AMs were 
transfected with AZI siRNA or scrambled siRNA and then treated with BALF from 
Dex-Pc rats. Three days after transfection, cytosolic cytochrome c levels were measured. 
Results represent mean ± S.D. from three experiments. Asterisk (*) indicates p < 0.05 as 
compared to scrambled control. 
 
 
 82
Caspase-3 Activation after siRNA Knockdown of AZI 
 
 
 
 
 
 
 
Fig. 18. Caspase-3 activation after siRNA knockdown of AZI. Normal rat AMs were 
transfected with AZI siRNA or scrambled siRNA and then treated with BALF from 
Dex-Pc rats. Three days after transfection, the level of activated caspase-3 in AMs was 
determined Western blotting. 
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Dex-Pc BALF Induces AZI Overexpression 
 
 
 
 
 
 
 
Fig. 19. Dex-Pc BALF induces AZI overexpression (A) Normal rat alveolar macrophages 
were incubated with Normal, Dex and Dex-Pc BALF for 24 hours and then examined by 
real-time RT-PCR for AZI expression. Results represent mean ± S.D. from five 
experiments. Asterisk (*) indicates p < 0.05 as compared to the Dex control. 
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Pneumocystis and Zymosan Induce AZI Overexpression 
 
 
 
 
 
 
 
 
Fig. 20. Pneumocystis and zymosan induce AZI overexpression. Normal rat AMs were 
incubated with TNF-α (TNF, 100 - 800 pg/μl), Pneumocystis carinii organisms (Pc, 20 - 
160 nuclei/μl), or zymosan A (Zymo, 40 - 320 ng/μl) for 18 hours and then examined by 
real-time RT-PCR for AZI expression. Results represent mean ± S.D. from three analyses. 
Asterisk (*) indicates p < 0.05 as compared to mock control. 
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PAO and SMO mRNA Expressions in AMs 
 
 
 
 
 
 
 
Fig. 21. PAO and SMO mRNA expressions in AMs. mRNA levels of PAO and SMO in 
AMs from Normal, Dex, and Dex-Pc rats were determined by real time RT-PCR. Results 
represent means ± SD from 5 experiments. Asterisk (*) indicates p < 0.05 as compared to 
Dex control. 
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PAO Protein Expression in AMs 
 
 
 
 
 
 
Fig. 22. PAO protein expression in AMs. Protein levels of PAO in AMs from Normal, 
Dex, and Dex-Pc rats were determined by Western blotting. 
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PAO and SMO Activities in AMs 
 
 
 
 
 
 
 
Fig. 23. PAO and SMO activities in AMs. The enzyme activities of PAO and SMO in 
AMs from Normal, Dex, and Dex-Pc rats were determined. Results represent mean ± S.D. 
from 5 experiments. Asterisk (*) indicates p < 0.05 as compared to Dex control. 
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Polyamines Induce PAO mRNA Expression 
 
 
 
 
 
 
 
Fig. 24. Polyamines induce PAO mRNA expression. RAW 264.7 cells were incubated 
with spermidine (SPD), spermine (SPM), N1-acetylspermidine (NSPD), and 
N1-acetylspermine (NSPM) at indicated concentrations (20-160 μM) for 24 hr. The PAO 
mRNA levels of polyamine-treated cells were analyzed by real time RT-PCR. Results 
represent mean ± S.D. from five analyses. 
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Polyamines Induce PAO Protein Expression 
 
 
 
 
 
 
 
Fig. 25. Polyamines induce PAO protein expression. RAW 264.7 cells were incubated 
with spermidine (SPD), spermine (SPM), N1-acetylspermidine (NSPD), and 
N1-acetylspermine (NSPM) at indicated concentrations (0-160 μM) for 24 hr. The PAO 
protein levels of polyamine-treated cells were analyzed by Western blotting. 
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Structures of Polyamine Transport Inhibitors 
 
 
 
 
 
 
 
Fig. 26. Structures of polyamine transport inhibitors. 
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Cytotoxicity of Polyamine Transport Inhibitors 
 
 
 
 
 
 
 
Fig. 27. Cytotoxicity of polyamine transport inhibitors. AMs from normal rats were 
incubated with polyamine transport inhibitors at indicated concentrations for 3 hr and 
then examined for viability by the Trypan blue exclusion method. 
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Rat Survival after 44-Ant-44 and 44-Bn-44 Treatments 
 
 
 
 
 
 
 
Fig. 28. Rat survival after 44-Ant-44 and 44-Bn-44 treatments. Eight rats each with PcP 
(Dex-Pc rats) were treated with 44-Ant-44 or 44-Bn-44 by intranasal instillation of 50 μl 
of 1 mM of the compound every two days starting at the 28th day after infection. 
Untreated Dex-Pc (n = 9) and uninfected Dex (n = 4) rats were used as controls. The 
numbers of treated and untreated rats survived were recorded daily for 84 days from the 
day of infection. 
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Pulmonary Pathology after 44-Ant-44 and 44-Bn-44 Treatments 
 
 
 
 
 
Fig. 29. Pulmonary pathology after 44-Ant-44 and 44-Bn-44 treatments. The effects of 
44-Ant-44 and 44-Bn-44 on PcP-mediated pulmonary damage were examined after three 
weeks of treatment. (A) Microscopic observation of H&E stained lung sections 
(magnification = 100 ×). (B) Severity of inflammation. The degree of inflammation was 
graded with a scale of 0 to 5. Results shown are representative images or means ± SD of 
three 44-Bn-44-treated, five 44-Ant-44-treated, and four untreated Dex and Dex-Pc rats. 
Asterisk (*) indicates p < 0.05 as compared to Dex-Pc group. 
 94
Pneumocystis Burden after 44-Ant-44 and 44-Bn-44 Treatments 
 
 
 
 
 
Fig. 30. Pneumocystis burden after 44-Ant-44 and 44-Bn-44 treatments. The effects of 
44-Ant-44 and 44-Bn-44 on Pneumocystis burden were examined by silver staining on 
lungs after three weeks of treatment. (A) Microscopic observation of silver-stained lung 
sections (magnification = 100 ×). (B) Organism burden was scored 0 to 4. Results shown 
are representative images or means ± SD of three 44-Bn-44-treated, five 
44-Ant-44-treated, and four untreated Dex and Dex-Pc rats. Asterisk (*) indicates p < 
0.05 as compared to Dex-Pc group. 
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AM Apoptosis after 44-Ant-44 and 44-Bn-44 Treatments 
 
 
 
 
 
 
Fig. 31. AM Apoptosis after 44-Ant-44 and 44-Bn-44 treatments. The effects of 
44-Ant-44 and 44-Bn-44 on pulmonary apoptosis was examined by TUNEL assay 
performed on lung sections after three weeks of treatment. Green dots represent the 
nuclei of apoptotic cells. Cell nuclei were stained blue with DAPI. Magnification = 100 ×. 
Results shown are representative images of three 44-Bn-44-treated, five 
44-Ant-44-treated, and four untreated Dex and Dex-Pc rats. 
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DISCUSSION 
 
Polyamines are essential molecules for all cells. However, elevated levels of 
intracellular polyamines are associated with diseases, such as cancers (38) and with 
susceptibility to infections by microorganisms such as H. pylori (32) and Pneumocystis 
(105). The levels of spermidine, N1-acetylspermidine, and N1-acetylspermine in both the 
alveoli and AMs are elevated, leading to increased rate of AM apoptosis during PCP 
(105). In this study, possible mechanisms for the great increase in polyamine levels were 
investigated. The transcription of the ODC gene, which encodes the key enzyme in 
polyamine synthesis in AMs was found not affected by Pneumocystis infection. However, 
the ODC protein level in AMs was greatly (8 fold) increased during PCP (Fig. 5), 
indicating that the balance between ODC synthesis and degradation is altered during 
Pneumocystis infection. As described above, the ODC protein level is controlled by both 
OAZ and AZI. OAZ binds to ODC and transports it to the 26s proteasome for 
degradation, whereas AZI competes with ODC for binding to OAZ. When AZI binds to 
OAZ, less ODC is degraded and thus a steady-state level of polyamines in the cells is 
maintained. Since OAZ mRNA and protein levels were not changed (Fig. 11) but both the 
mRNA (3 fold) and protein (6 fold) levels of AZI were greatly increased (Fig. 12), it is 
likely that the ODC turnover rate in AMs during PCP is decreased due to AZI 
overexpression. The result that AZI knockdown by siRNA decreased the ODC protein 
level by 60% (Fig. 14) confirmed this possibility, although the intracellular polyamine 
levels afte AZI knockdown were not measured. Higher polyamine synthesis during PCP 
was demonstrated by an IHC experiment in which ODC-positive cells, mainly 
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inflammatory cells, were shown to react with the anti-spermidine antibody (Fig. 10 & 
Table 1), indicating polyamine synthesis in these cells. 
This study used rats instead of mice as PCP model mainly to take advantage of much 
higher alveolar macrophage yields. Since the rats were immunosuppressed with 
dexamethasone, there is always a concern whether dexamethasone also affects ODC 
expression or activity. To control for this effect, both normal and dexamethasone-treated 
rats were used as controls. In all the experiments performed in this study, results derived 
from dexamethasone-treated rats were very similar to those from normal rats. Therefore, 
dexamethasone did not appear to have a significant effect on polyamine synthesis or 
uptake examined in this study. Previous studies by another group showed that treatment 
of normal rats with dexamethasone actually decreased ODC activity in their lungs (13). 
Therefore, the increased ODC activity observed in alveolar macrophages during PCP was 
not due to dexamethasone treatment but due to Pneumocystis infection. 
An interesting finding in this study is that ODC distribution in inflammatory cells 
was changed from cytoplasmic to pericytoplasmic (Fig. 9). ODC translocation has been 
shown to be associated with cell cycle progression (186) or cell activation and 
transformation (72). Since inflammatory cells are activated when they are recruited to the 
lung, it is very likely that the change in ODC distribution is due to cell activation during 
PCP and that this activation leads to elevated polyamine synthesis. 
In addition to increased synthesis, increased uptake of exogenous polyamines is 
another possible cause of elevated polyamine levels in AMs during PCP. However, 
polyamine transporters in mammalian cells remain largely unknown. Synthetic 
fluorescent polyamines have been used to explore mammalian polyamine transport 
systems (23, 127, 128), and a receptor-mediated endocytosis mechanism has been 
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suggested (23, 127). Another study showed that polyamine uptake was unaffected in 
endocytosis-deficient cells and that the internalized polyamines were colocalized with 
acidic vesicles of the late endocytic compartment and the trans Golgi (128). This finding 
suggests that polyamines are imported by a membrane carrier (128). The mammalian 
polyamine transport systems appear to have a broad substrate specificity and can 
transport a variety of polyamines (41). Therefore, it is possible that the spermidine uptake 
system (Fig. 7) is also responsible for the uptake of N1-acetylspermidine and 
N1-acetylspermine into AMs during PCP. Polyamine uptake assays are commonly 
performed using radioactive polyamines (50, 117, 147). Aziz et al. (9) and Aouida et al. 
(1) used fluorescein-labeled polyamines to perform these assays in cultured cells and 
yeasts by fluorescence microscopy. It was demonstrated that the fluorescein moiety does 
not affect the transport of polyamines (9). In this study, fluorescein-labeled spermidine 
was used to investigate polyamine uptake in Pneumocystis-infected rats showed for the 
first time that FAM-labeled spermidine can be used for polyamine uptake assay in vivo 
(Fig. 7). 
Although the number of AMs which took up fluorescent spermidine (FAM-SPD) in 
the polyamine uptake assay was found to be 20 fold higher in Pneumocystis-infected than 
in uninfected rats, only approximately 2% of AMs in Pneumocystis-infected rats 
internalized FAM-SPD (Fig. 7). The reason for this low number of cells taking up 
FAM-SPD is unknown. It may be that most AMs in Pneumocystis-infected lungs already 
contain high levels of polyamines (105) and are no longer able to take up exogenous 
polyamines. The AMs that took up FAM-SPD in the polyamine uptake assay were 
probably those containing lower levels of intracellular polyamines. This possibility 
remains to be investigated.  
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Since overexpression of AZI has been shown to increase polyamine uptake (88), it is 
conceivable that the increased level of AZI in AMs contributes to this increased uptake of 
exogenous polyamines. The result that AZI expression knockdown by siRNA decreased 
the number of cells that can take up polyamines by 50% (Fig. 15) strongly supports this 
possibility. A likely source of exogenous polyamines is Pneumocystis organisms, as they 
have been shown to produce and secrete polyamines, mainly N1-acetylspermine and 
N1-acetylspermidine (134). Since SSAT levels were not increased in AM during PCP 
(Fig. 4 & 5), the elevated levels of acetylated polyamines in AMs are more likely due to 
uptake of such polyamines from exogenous sources. Like SSAT, the expression level of 
the spermidine synthase, which converts putrescine to spermidine, was also not increased 
in AM during PCP (Fig. 4), suggesting that spermidine synthase is not responsible for the 
increased spermidine level. It is possible that the increased spermidine level is due to 
conversion of N1-acetylspermine to spermidine. 
Pneumocystis has been shown to produce and excrete high levels of 
N1-acetylspermine and N1-acetylspermidine due to high levels of polyamine catabolism 
rate in an in vitro study (134). Taken together with the results that SSAT expression was 
not increased in AMs during PCP, the high levels of these acetylated polyamines in AMs 
during PCP are likely due to uptake of polyamines produced by Pneumocystis. To 
investigate whether other host cells could also contribute to the acetylated polyamine 
pool, IHC staining for SSAT on lungs with PCP was performed; unfortunately, the results 
showed too much background and were not interpretable. A recent unpublished data 
(from Dr. Merali, Temple University) indicated that AMs from SSAT-KO mice with PCP 
also contain high levels of N1-acetylspermine and N1-acetylspermidine. These results 
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further suggest that the increased levels of acetylated polyamines in AMs during PCP are 
more likely due to uptake of acetylated polyamines produced by Pneumocystis. 
In addition to Pneumocystis organisms, inflammatory cells are another possible 
source of polyamines as they were stained positive for ODC (Table 1), and spermidine 
levels were high in these cells (Fig. 10). These cells were mainly located around blood 
vessels and bronchioles (Fig. 10) and therefore are considered inflammatory cells that are 
recruited into the lung during PCP. Approximately 25% of the total lung cells from 
infected rats were ODC positive. These inflammatory cells were shown by flow 
cytometry to be CD4+ T cells (1.83%), CD8+ T cells (9.79%), B cells (9.79%), and 
CD68+ cells (7.80%) that may be monocytes or macrophages. In this study, ODC was 
found to be present only in inflammatory cells by IHC staining (Fig. 9) and flow 
cytometry (Table 1), indicating that ODC levels are higher in inflammatory cells than in 
other types of pulmonary cells and these inflammatory cells could possiblely contribute 
to the exogenenous polyamine pool. However, these polyamines must be transported 
through pulmonary parenchyma to alveoli. Such transport system has not been identified. 
Conversion of N1-acetylspermine to spermidine and N1-acetylspermidine to 
putrescine by PAO is accompanied by the production of H2O2 which may damage 
mitochondria leading to induction of apoptosis. This mechanism is thought to be 
responsible for the loss of AMs during PCP as ROS levels are increased in AMs during 
PCP (105). Since the mRNA, protein expression, and enzymatic activity levels of PAO 
were all increased in AMs during PCP (Fig. 21, 22 & 23), it is conceivable that the ROS 
generated by PAO plays an important role in AM apoptosis during Pneumocystis 
infection. It is possible that PAO overexpression in AMs during PCP is induced by the 
increased intracellular levels of PAO substrates N1-acetylspermidine and 
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N1-acetylspermine (105). Although attempts were made to measure H2O2 levels in AMs, 
the readings from all groups were too low to interpretate, probably due to the fast 
conversion among different ROS. 
An important finding in this study is that AZI expression knockdown by siRNA 
resulted in a 53% decrease in the number of apoptotic AMs (Fig. 16), a 58% decrease in 
cytosolic cytochrome c levels (Fig. 17), and a 75% decrease in the level of activated 
caspase-3 (Fig. 18). This result indicates that decreasing AZI protein levels also decreases 
the apoptosis rate of AMs. It is possible that the reduction in AZI levels causes a 
decreased uptake of exogenous acetylated polyamines; therefore, less acetylated 
polyamines are available to be converted to regular polyamines, and thus less H2O2 is 
produced to trigger apoptosis. This is the first demonstration that AZI is involved in 
apoptosis. A previous study showed that transfection of the gene encoding OAZ, the 
negative regulator of AZI, can also to induce apoptosis by activating mitochondrial 
depolarization and caspase cascade (83). It is not surprising that both OAZ and AZI have 
a pro-apoptotic activity due to the multiple roles of polyamines (38, 122). 
Polyamines have also been found to be involved in the pathogenesis of Helicobacter 
pylori. H. pylori activates the transcriptional factor c-Myc which induces ODC 
expression, resulting in increased intracellular polyamine pools in macrophages (18). 
This polyamine accumulation greatly reduces the uptake of L-arginine which is the 
substrate of inducible nitric oxide synthase (iNOS) and is also the rate-limiting factor for 
iNOS translation (31). Therefore, increased polyamine levels consequently decrease the 
synthesis of iNOS in macrophages and result in loss of innate immune responses against 
H. pylori infection (10). H. pylori also activates SMO to convert spermidine to spermine 
accompanied by generation of H2O2 which causes macrophages to undergo apoptosis (16, 
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166). Therefore, induction of apoptosis by polyamines appears to be a survival 
mechanism for microbes to evade the clearance by immune systems. 
Although both Pneumocystis and H. pylori cause macrophages to undergo apoptosis 
due to elevated levels of polyamines, the mechanisms in polyamine acquisition are 
different. Unlike H. pylori, Pneumocystis does not upregulate ODC synthesis. Instead, it 
upregulates AZI expression leading to increased uptake of exogenous polyamines and 
decreased degradation of ODC thus increasing polyamine synthesis. Therefore, the 
increase in polyamine levels in AMs during PCP is due to both increased uptake and 
polyamine synthesis. Upregulation of AZI expression has also been shown in other 
diseases. A comparative clinical study showed that gastric cancer tissue removed during 
surgery expresses higher levels of AZI than the surrounding normal tissue (83). Oncogene 
Ras transformed NIH3T3 cells also have increased AZI expression (88). Although AZI 
levels have been shown to be increased in a number of conditions, the mechanisms for 
AZI overexpression were largely unknown. In this study, both Pneumocystis organisms 
and zymosan A were found to induce AZI expression in a dose-dependent manner (Fig. 
20). Since the major component of zymosan A is β-glucan which is also the major 
component of Pneumocystis cell wall, it is very likely that β-glucan induces AZI 
overexpression in AMs. The dectin-1 receptor has been shown to be the main receptor for 
β-glucan on AMs (23), and binding of β-glucan to dectin-1 has been shown to activate the 
NF-B signaling pathway (65). Therefore, it is possible that AZI expression is regulated 
by NF-B. This possibility is being investigated. 
The phenomenon of increased polyamine levels in AMs during PCP is very similar 
to that in cancers. The major cause of increase in polyamine levels in cancer cells is 
increased synthesis of polyamines due to increased levels of ODC. Therefore, inhibition 
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of ODC activity with DFMO is a potential therapy for cancer. Unfortunately, clinical 
trials show that DFMO has no or little effect against cancers (114, 159, 224). One 
possible reason for this treatment failure is the increased uptake of exogenous 
polyamines, which compensates the loss of polyamine synthesis during DFMO therapy 
(74). 
Although DFMO therapy has not been successful in cancer, it was found to be very 
effective against trypanosomiasis. The selective toxicity of DFMO to Trypanosoma is 
probably due to the huge difference in the half-life of Trypanosoma (more than 10 hr) and 
mammalian ODC (10 - 20 min). Since Trypanosoma ODC has a very long half-life, ODC 
molecule numbers may be low. Therefore, Trypanosoma ODC is more susceptible to 
DFMO inhibition. In addition, Trypanosoma do not have a mechanism of exogenous 
polyamine uptake to compensate for the loss of polyamines synthesis due to DFMO 
treatment (11). 
DFMO has also been used to treat PcP. The effect of DFMO on 
Pneumocystis-infected animals is controversial. One animal study showed that 
Pneumocystis-infected rats receiving 3% DFMO in drinking water had a significant 
decrease in organism burden after three weeks of treatment (p < 0.001) (36). In contrast, 
another study showed that DFMO was ineffective against PCP under a similar treatment 
condition (229). Human clinical trials revealed that 57% of patients with PCP responded 
to DFMO treatment (192), suggesting that inhibition of polyamine synthesis is a viable 
therapeutic approach against PcP. 
The actual target of DFMO in the treatment of PCP is not well defined. ODC 
activity was reported to be absent in Pneumocystis organisms in at least two independent 
studies (120, 167). In this case, host ODC would be the only target of DFMO. However, 
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a later study reported the presence of ODC activity in dialyzed Pneumocystis extracts 
(185). Another study performed by the same group demonstrated that polyamine levels 
in Pneumocystis extracts were decreased after DFMO treatment. This result supports 
their conclusion as to the presence of Pneumocystis ODC, and its potential as a target of 
DFMO (135). 
Although DFMO has a certain degree of therapeutic activity against PCP, it is not 
completely effective, indicating that targeting polyamine synthesis alone is not sufficient 
for PcP treatment. Our previously studies have found that AM apoptosis is a cause of 
disease progression during PcP (103) and that this apoptosis is triggered by increased 
polyamine levels due to both increased synthesis and uptake of polyamines (115). These 
findings may explain the partial success of DFMO therapy against PCP, because DFMO 
only inhibits polyamine synthesis, not uptake. 
In this study, we used aryl-polyamine conjugates, which target the polyamine 
transport (PAT) with high affinity and inhibit uptake of native polyamines. Two 
compounds, 44-Ant-44 and 44-Bn-44, were tested in vivo, and 44-Ant-44 was found to 
reduce organism burden (Fig. 30), decrease lung inflammation (Fig. 29), and prolonged 
survival of treated PcP animals by more than eight days (Fig. 28). It is possible that the 
effectiveness of this treatment is due to decreased rate of apoptosis of AMs (Fig. 31) as 
polyamine transport ligands would block polyamine uptake and thus decrease the levels 
of intracellular polyamines. This action leads to decreased production of H2O2. As the 
result, AMs survive to clear the organisms, thus reducing organism burden and lung 
inflammation leading to longer survival. 
Polyamine transport inhibitors can be structurally classified into two major types: 
polyamine polymer and polyamine-lysine conjugate. The homodimers of putrescine (39) 
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and spermine (66, 79) and polymer of spermine (8) have been shown to effectively 
inhibit polyamine transport. Simple lysine-spermine conjugate (34, 238) and lipophilic 
lysine-spermine (26) also exhibit polyamine transport inhibition activity. 44-Ant-44, the 
compound shown to have anti-PCP activity in this study, is structurally similar to a 
spermidine dimer crosslinked by a 9,10-bis-substituted-anthraldehyde. 
In a recent report, 44-Ant-44 was shown to have the highest polyamine transport 
inhibition activity in a Chinese hamster ovary (CHO) screen (86, 169). The screen 
utilized two CHO cell lines: the PAT-active wild type CHO K-1 line and the 
PAT-defective CHO-MG line. Comparison of conjugate cytotoxicity in these two CHO 
lines provided an important tool to detect selective conjugate delivery via the PAT. A 
conjugate with high utilization of the PAT would be very toxic to CHO cells, but less so 
to CHO-MG cells. Highly selective PAT ligands should give high (CHO-MG/CHO) 
IC50 ratios. As shown in Table 1, 44-Ant-44 and 44-Bn-44 were the most PAT-selective 
of the series with CHO-MG/CHO IC50 ratios >600. One potential explanation of why 
44-Ant-44 was superior to the benzyl derivative 44-Bn-44 is cellular metabolism. For 
example, a benzyl-homospermidine model compound was shown to be metabolized to 
homospermidine in cell culture, whereas the anthryl-homospermidine was not (232). 
This is rationalized due to significant steric constraints near the benzylic position of the 
anthryl platform, which may impede the action of amine oxidases (169). 
Although, inhibition of polyamine uptake with compound 44-Ant-44 showed 
impressive results, it did not cure the disease. This is expected as the increase of both 
ODC levels and uptake of exogenous polyamines account for the increased polyamine 
levels during PCP. Studies using both the ODC inhibitor DFMO and polyamine transport 
ligand 44-Ant-44 to treat PCP are being conducted. This combination therapy is expected 
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to be a more effective PCP treatment as a synergistic effect has been shown in cancer 
therapy (26, 34). Because of the limited supply of the compound, only one dosage and 
one treatment condition were tested in the current study. Additional dosages remain to be 
tested to determine whether a lower dose also works or whether a higher dose of the 
compound would be more effective. Other methods of drug delivery, such as placing the 
drug in drinking water, also need to be explored. Successful development of combination 
therapy may have a great impact on cancer therapy, as cancers also have increased 
polyamine synthesis and uptake (61, 182).  
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FUTURE STUDIES 
 
Based on results of this study, the following studies should be conducted to further 
characterize polyamine-mediated apoptosis of AMs and to develop polyamine transport 
as a target for treatment of PCP. 
 
1. Investigate the mechanisms by which Pneumocystis induces AZI over-expression. 
The possibility that Pneumocystis β-glucan stimulates AMs to increase AZI 
expression needs to be confirmed. Other Pneumocystis components such as MSG, 
mannan, and chitin that may also be involved in Pneumocystis-induced AZI 
over-expression should be identified, and the receptors that transmit the signal 
leading to AZI over-expression need to be determined. The transcription factors that 
cause AZI over-expression in AMs during PCP should also be investigated.   
 
2. Investigate blocking polyamine transport as a target for treatment of PCP. The PAT 
inhibitor 44-Ant-44 shows promise as a therapy for PCP, based upon the observation 
that it prolonged the survival of animals with PCP. In order to evaluate its potential 
usefulness, the optimal dosage, delivery route, and frequency of 44-Ant-44 
administration need to be determined. Additional PAT inhibitors or derivatives of 
44-Ant-44 need to be developed and tested to identify the most effective PAT 
inhibitor for therapy of PCP. Treatment of PCP with PAT inhibitor(s) alone and in 
combination with the polyamine synthesis inhibitor DFMO or the conventional 
therapy of TMP/SMZ for therapeutic efficacy against PCP in animal models should 
be conducted. 
 108
3. Investigate polyamine metabolism as a target for treatment of PCP. PAO expression 
and activity are increased in AMs during PCP, leading to production of excess H2O2 
that triggers AMs to undergo apoptosis. The possibility that inhibiting PAO activity 
will prevent AMs from undergoing apoptosis and prolong the survival of infected 
animals need to be examined. 
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